WO2023226580A1 - 吡咯并嘧啶类化合物,其制备方法及制药用途 - Google Patents
吡咯并嘧啶类化合物,其制备方法及制药用途 Download PDFInfo
- Publication number
- WO2023226580A1 WO2023226580A1 PCT/CN2023/084066 CN2023084066W WO2023226580A1 WO 2023226580 A1 WO2023226580 A1 WO 2023226580A1 CN 2023084066 W CN2023084066 W CN 2023084066W WO 2023226580 A1 WO2023226580 A1 WO 2023226580A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- room temperature
- add
- butyl
- tert
- methyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 74
- -1 Pyrrolopyrimidine compound Chemical class 0.000 title claims description 39
- 150000001875 compounds Chemical class 0.000 claims abstract description 76
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 273
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 198
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 114
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 44
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 42
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 40
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 38
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 34
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 20
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 claims description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 9
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 claims description 5
- KKLCYBZPQDOFQK-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-phenyl-1,3,2-dioxaborolane Chemical class O1C(C)(C)C(C)(C)OB1C1=CC=CC=C1 KKLCYBZPQDOFQK-UHFFFAOYSA-N 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 229910001948 sodium oxide Inorganic materials 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 20
- 206010028980 Neoplasm Diseases 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 abstract description 8
- 206010025323 Lymphomas Diseases 0.000 abstract description 5
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 3
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical group N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 106
- 238000003756 stirring Methods 0.000 description 98
- 239000012141 concentrate Substances 0.000 description 75
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 74
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 67
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 66
- 239000007787 solid Substances 0.000 description 62
- 238000002844 melting Methods 0.000 description 60
- 230000008018 melting Effects 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 59
- 238000004440 column chromatography Methods 0.000 description 37
- 239000003480 eluent Substances 0.000 description 37
- 239000003208 petroleum Substances 0.000 description 37
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 26
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 26
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 description 19
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 19
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000000126 substance Substances 0.000 description 17
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 13
- 229910052786 argon Inorganic materials 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 13
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 12
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 12
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 10
- UFBHSXXPAZMVSI-UHFFFAOYSA-N but-2-ynoyl chloride Chemical compound CC#CC(Cl)=O UFBHSXXPAZMVSI-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 7
- 229960001507 ibrutinib Drugs 0.000 description 7
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 7
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 7
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 7
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 235000011056 potassium acetate Nutrition 0.000 description 6
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 5
- RLTFBWCBGIZCDQ-UHFFFAOYSA-N (4-bromo-2-fluorophenyl)methanamine Chemical compound NCC1=CC=C(Br)C=C1F RLTFBWCBGIZCDQ-UHFFFAOYSA-N 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- WNLMYNASWOULQY-UHFFFAOYSA-N 4-tert-butylbenzoyl chloride Chemical compound CC(C)(C)C1=CC=C(C(Cl)=O)C=C1 WNLMYNASWOULQY-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108091008875 B cell receptors Proteins 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- XXGYVFAKVLKYMQ-UHFFFAOYSA-N 2-[(4-chloro-5-iodopyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl-trimethylsilane Chemical compound N1=CN=C2N(COCC[Si](C)(C)C)C=C(I)C2=C1Cl XXGYVFAKVLKYMQ-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 101100297694 Arabidopsis thaliana PIP2-7 gene Proteins 0.000 description 2
- 229940124291 BTK inhibitor Drugs 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- AXIRUTHKBIOYDP-UHFFFAOYSA-N N-[(4-bromo-2-methylphenyl)methyl]-4-tert-butylbenzamide Chemical compound BrC1=CC(=C(CNC(C2=CC=C(C=C2)C(C)(C)C)=O)C=C1)C AXIRUTHKBIOYDP-UHFFFAOYSA-N 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 101100456541 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MEC3 gene Proteins 0.000 description 2
- 101100483663 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UFD1 gene Proteins 0.000 description 2
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- XXPZPNNJFZAXFB-UHFFFAOYSA-N n-[(4-bromo-2-fluorophenyl)methyl]-4-tert-butylbenzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)NCC1=CC=C(Br)C=C1F XXPZPNNJFZAXFB-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000004944 pyrrolopyrimidines Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001875 tumorinhibitory effect Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- CRDQDMSHRCFAAW-UHFFFAOYSA-N (4-bromo-2-methylphenyl)methanamine Chemical compound CC1=CC(Br)=CC=C1CN CRDQDMSHRCFAAW-UHFFFAOYSA-N 0.000 description 1
- XRNVSPDQTPVECU-UHFFFAOYSA-N (4-bromophenyl)methanamine Chemical compound NCC1=CC=C(Br)C=C1 XRNVSPDQTPVECU-UHFFFAOYSA-N 0.000 description 1
- BUVVJIGULSJYLF-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylic acid Chemical compound O1C(C)(C)C(C)(C)OB1C1=CCN(C(O)=O)CC1 BUVVJIGULSJYLF-UHFFFAOYSA-N 0.000 description 1
- CBWBJFJMNBPWAL-UHFFFAOYSA-N 4-chloro-5-iodo-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C(I)=CN2 CBWBJFJMNBPWAL-UHFFFAOYSA-N 0.000 description 1
- PFLSDXYKTMMDEA-UHFFFAOYSA-N 4-cyclopropylbenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1C1CC1 PFLSDXYKTMMDEA-UHFFFAOYSA-N 0.000 description 1
- ZFZVLJVQRGSKEA-UHFFFAOYSA-N 4-tert-butyl-N-[[2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]benzamide Chemical compound C(C)(C)(C)C1=CC=C(C(=O)NCC2=C(C=C(C=C2)B2OC(C(O2)(C)C)(C)C)C)C=C1 ZFZVLJVQRGSKEA-UHFFFAOYSA-N 0.000 description 1
- DBOVTNHXQKMGFL-UHFFFAOYSA-N 4-tert-butyl-N-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]benzamide Chemical compound C(C)(C)(C)C1=CC=C(C(=O)NCC2=CC=C(C=C2)B2OC(C(O2)(C)C)(C)C)C=C1 DBOVTNHXQKMGFL-UHFFFAOYSA-N 0.000 description 1
- DKOSWVRTGFUOMJ-UHFFFAOYSA-N 4-tert-butyl-n-[[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)NCC1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1F DKOSWVRTGFUOMJ-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101150037263 PIP2 gene Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 102100026857 Tyrosine-protein kinase Lyn Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000002796 luminescence method Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention relates to the field of medicine, and specifically to a class of compounds containing pyrrolopyrimidine structures or pharmaceutically acceptable salts thereof, their preparation methods, pharmaceutical compositions containing such compounds, and the use of such compounds in the preparation and treatment of Bruton Application in drugs for diseases related to Bruton's tyrosine kinase (BTK) function.
- BTK Bruton's tyrosine kinase
- Tyrosine protein kinase is a type of kinase that catalyzes the transfer of ⁇ -phosphate from ATP to protein tyrosine residues. It can catalyze the phosphorylation of tyrosine residues in a variety of substrate proteins. It plays a very important role in signal transduction pathways, regulating a series of physiological and biochemical processes such as cell growth, differentiation, and death. Dysfunction of tyrosine protein kinases will cause a series of diseases in organisms.
- BTK is one of the main members of the Tec family of tyrosine protein kinases.
- BTK is a key kinase in the B-cell receptor (BCR) signal transduction pathway.
- BCR B-cell receptor
- phosphorylated PI3K phosphatidylinositol 3-kinase
- PIP3 binds to the PH domain of BTK, BTK is subsequently recruited to the cell membrane, and Tyr-551 residue is subsequently phosphorylated by SYK and LYN kinases.
- BTK then undergoes an autophosphorylation reaction at Tyr-223 residue to become physiologically active.
- Activated BTK activates many downstream pathways, such as downstream protein kinase C, nuclear factor kappa-B (NF- ⁇ B), MAPK pathway, etc., and has an important impact on multiple cellular processes of B cells, such as growth, development, differentiation, and apoptosis. .
- BTK plays an important role in B cell-related malignancies, such as acute B lymphoblastic leukemia, non-Hodgkin's lymphoma, and autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus and other diseases. This makes BTK a potential target for B-cell malignancies and autoimmune diseases.
- Existing BTK inhibitors have poor selectivity and low bioavailability, resulting in large clinical dosages and large toxic and side effects. Therefore, there is an urgent need to discover new BTK inhibitors with high activity and good druggability.
- the invention provides a class of compounds containing pyrrolopyrimidine structures or pharmaceutically acceptable salts thereof, their preparation methods, pharmaceutical compositions containing such compounds, and the use of such compounds in preparing drugs for treating diseases related to BTK function. applications in.
- the present invention provides the following technical solutions:
- the first aspect of the technical solution of the present invention is to provide a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof:
- R is selected from And R 3 is selected from acryloyl, 2-butynoyl;
- R 1 and R 2 substituents are one or more, selected from H, C 1-8 linear or branched alkyl, C 3-8 cycloalkyl, C 1-8 alkoxy, C 1-8 alkyl amino group, halogen, hydroxyl, amino group, cyano group, and the C 1-8 linear or branched alkyl group is further substituted by one or more halogen, hydroxyl, amino or cyano group.
- R 1 and R 2 are selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl Base, tert-butyl, n-pentyl, isopentyl, cyclopropyl, cyclobutyl, cyclopentyl, methoxy, ethoxy, propoxy, methylamino, ethylamino, F, Cl, Br, I, hydroxyl, amino, cyano, or selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl substituted by one or more halogens Base, isopentyl.
- R 1 is selected from H, methyl, ethyl, trifluoromethyl, F, Cl, Br, or I
- R 2 is selected from From H, isopropyl, isobutyl, tert-butyl, isopentyl, cyclopropyl, cyclobutyl, cyclopentyl.
- the pharmaceutically acceptable salt is selected from organic acid salts or inorganic acid salts, including but not limited to hydrochlorides, hydrobromides, sulfates, phosphates, acetates, citrates, malates, rich salts, Malate, tartrate or methanesulfonate.
- the compound of general formula (I) has the following structure:
- Another aspect of the technical solution of the present invention is to provide a synthetic method for a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.
- the synthetic route is as follows:
- Reagents and conditions (a) (2-(chloromethoxy)ethyl)trimethylsilane, potassium carbonate, N,N-dimethylformamide, room temperature; (b) N-Boc-1,2, 5,6-Tetrahydropyridine-4-boronic acid pinacol ester, 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride, potassium carbonate, 1,4-dioxane, 100°C ; (c) R 1 , R 2 substituted phenylboronic acid pinacol ester, 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride, potassium carbonate, 1,4-dioxane, 100°C; (d) ethanol solution of hydrochloric acid, room temperature; acryloyl chloride, N,N-diisopropylethylamine, dichloromethane, room temperature; (e) trifluoroacetic acid, dichlorome
- Reagents and conditions (a) (2-(chloromethoxy)ethyl)trimethylsilane, potassium carbonate, N,N-dimethylformamide, room temperature; (b) N-Boc-1,2, 5,6-Tetrahydropyridine-4-boronic acid pinacol ester, 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride, potassium carbonate, 1,4-dioxane, 100°C ; (c) R 1 , R 2 substituted phenylboronic acid pinacol ester, 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride, potassium carbonate, 1,4-dioxane, 100°C; (d) hydrogen, palladium on carbon, ethyl acetate solution, methanol solution, room temperature (e) ethanol solution of hydrochloric acid, room temperature; acryloyl chloride, N,N-diisopropyle
- R 1 and R 2 are the same as mentioned above.
- Another aspect of the technical solution of the present invention is to provide a pharmaceutical composition, characterized in that the pharmaceutical composition contains The aforementioned compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- Another aspect of the technical solution of the present invention is to provide the use of a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof in the preparation of drugs for treating diseases related to BTK function.
- Another aspect of the technical solution of the present invention is to provide the use of a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof in the preparation of medicines for the treatment of rheumatoid arthritis and systemic lupus erythematosus.
- Another aspect of the technical solution of the present invention is to provide the use of a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating non-Hodgkin's lymphoma, wherein the non-Hodgkin's lymphoma Golden lymphoma is preferably mantle cell lymphoma or diffuse large B-cell lymphoma.
- Another aspect of the technical solution of the present invention is to provide a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof for the preparation and treatment of Chinese macroglobulinemia, chronic lymphocytic leukemia or primary central nervous system disease. Use in lymphoma drugs.
- Example 8 has higher oral bioavailability, which is better than the marketed drugs.
- Ibrutinib has demonstrated strong tumor inhibitory activity in the TMD-8 animal model, showing good prospects for becoming a drug.
- Figure 1 In vivo tumor inhibitory effect of compounds.
- A Mouse weight-time curve;
- B Tumor volume-time curve;
- C Tumor weight-dose graph;
- D Photos of tumors in each group
- N-(4-bromo-2-fluorobenzyl)-4-(tert-butyl)benzamide (4.0572g, 0.011mol), pinacol diborate (4.2499g, 0.0165mol) and potassium acetate ( 3.2849g, 0.033mol) into the bottle, add 40mL of dioxane, stir evenly at room temperature, add Pd(dppf)Cl 2 (0.8164g, 0.0011mol), and heat to 100°C under argon protection for 6 hours.
- the reaction was cooled to room temperature, water was added, filtered under reduced pressure, the filtrate was collected, extracted three times with ethyl acetate, washed once with saturated sodium chloride solution, and dried over anhydrous sodium sulfate. Concentrate and separate by column chromatography.
- the melting point is 110-111
- the reaction was cooled to room temperature, water was added, filtered under reduced pressure, the filtrate was collected, extracted three times with ethyl acetate, washed once with saturated sodium chloride solution, and dried over anhydrous sodium sulfate. Concentrate and separate by column chromatography.
- the melting point is 75-76°C.
- the reaction was cooled to room temperature, water was added, filtered under reduced pressure, the filtrate was collected, extracted three times with ethyl acetate, washed once with saturated sodium chloride solution, and dried over anhydrous sodium sulfate. Concentrate and separate by column chromatography.
- N-(4-(5-(1-(but-2-ynyl)-1,2,3,6-tetrahydropyridin-4-yl)-7-((2-(trimethylsilyl) (yl)ethoxy)methyl)-7H-)pyrrolo[2,3-d]pyrimidin-4-yl)-2-fluorobenzyl)-4-(tert-butyl)benzamide (36 mg, 0.053 mmol) was dissolved in 600 ⁇ L dichloromethane, trifluoroacetic acid (280 ⁇ L, 3.71 mmol) was added dropwise under ice bath conditions, and stirred at room temperature for 7 h.
- N-(4-(5-(1-acryloyl-1,2,3,6-tetrahydropyridin-4-yl)-7-((2-(trimethylsilyl)ethoxy) Methyl)-7H-pyrrolo[2,3-)d]pyrimidin-4-yl)-2-fluorobenzyl)-4-(tert-butyl)benzamide 35 mg, 0.053 mmol was dissolved in 600 ⁇ L di Methyl chloride, add trifluoroacetic acid (280 ⁇ L, 3.71 mmol) dropwise in an ice bath, and stir at room temperature for 7 h. Add NaOH aqueous solution under ice bath conditions to adjust the pH to 7-8, and stir at room temperature for 1.5 hours.
- the reaction was cooled to room temperature, water was added, filtered under reduced pressure, the filtrate was collected, extracted three times with ethyl acetate, washed once with saturated sodium chloride solution, and dried over anhydrous sodium sulfate. Concentrate and separate by column chromatography.
- N-(4-(5-(1-acryloyl-1,2,3,6-tetrahydropyridin-4-yl)-7-((2-(trimethylsilyl)ethoxy) Methyl)-7H-pyrrolo[2,3-)d]pyrimidin-4-yl)benzyl)-4-(tert-butyl)benzamide (83mg, 0.1277mmol) was dissolved in 1.5mL dichloromethane, Trifluoroacetic acid (664 ⁇ L, 8.939 mmol) was added dropwise under ice bath conditions, and stirred at room temperature for 7 h. Add NaOH aqueous solution under ice bath conditions to adjust the pH to 7-8, and stir at room temperature for 1.5 hours.
- the reaction was cooled to room temperature, water was added, filtered under reduced pressure, the filtrate was collected, extracted three times with ethyl acetate, washed once with saturated sodium chloride solution, and dried over anhydrous sodium sulfate. Concentrate and separate by column chromatography.
- N-(4-(5-(1-(but-2-ynyl)-1,2,3,6-tetrahydropyridin-4-yl)-7-((2-(trimethylsilyl) (ethoxy)methyl)-7H-)pyrrolo[2,3-d]pyrimidin-4-yl)-2-fluorobenzyl)benzamide (76 mg, 0.122 mmol) was dissolved in 2 mL dichloromethane , add trifluoroacetic acid (815 ⁇ L, 10.98 mmol) dropwise under ice bath conditions, and stir at room temperature for 7 h. Add NaOH aqueous solution under ice bath conditions to adjust the pH to 7-8, and stir at room temperature for 1.5 hours.
- N-(4-(5-(1-acryloyl-1,2,3,6-tetrahydropyridin-4-yl)-7-((2-(trimethylsilyl)ethoxy) Methyl)-7H-pyrrolo[2,3-)d]pyrimidin-4-yl)-2-fluorobenzyl)benzamide (37mg, 0.06mmol) was dissolved in 1mL dichloromethane under ice bath conditions Trifluoroacetic acid (400 ⁇ L, 5.4 mmol) was added dropwise, and stirred at room temperature for 7 h. Add NaOH aqueous solution under ice bath conditions to adjust the pH to 7-8, and stir at room temperature for 1.5 hours.
- N-(4-bromo-2-fluorobenzyl)-4-cyclopropylbenzamide 360mg, 1.034mmol
- pinacol diborate 394mg, 1.551mmol
- potassium acetate 304mg, 3.102mmol
- Pd(dppf)Cl 2 76 mg, 0.1034 mmol
- the reaction was cooled to room temperature, water was added, filtered under reduced pressure, the filtrate was collected, extracted three times with ethyl acetate, washed once with saturated sodium chloride solution, and dried over anhydrous sodium sulfate. Concentrate and separate by column chromatography.
- the yield is 78.30%, and the melting point is 95-96°C.
- the reaction was cooled to room temperature, water was added, filtered under reduced pressure, the filtrate was collected, extracted three times with ethyl acetate, washed once with saturated sodium chloride solution, and dried over anhydrous sodium sulfate. Concentrate and separate by column chromatography.
- N-(4-(5-(1-acryloyl-1,2,3,6-tetrahydropyridin-4-yl)-7-((2-(trimethylsilyl)ethoxy) Methyl)-7H-pyrrolo[2,3-)d]pyrimidin-4-yl)-2-fluorobenzyl)-4-cyclopropylbenzamide 110 mg, 0.169 mmol was dissolved in 1 mL dichloromethane , add trifluoroacetic acid (1.13mL, 15.21mmol) dropwise under ice bath conditions, and stir at room temperature for 7h. Add NaOH aqueous solution under ice bath conditions to adjust the pH to 7-8, and stir at room temperature for 1.5 hours.
- N-(4-(5-(1-(but-2-ynyl)piperidin-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)- 7H-pyrrolo[2,3-d]pyrimidin)-4-yl)-2-fluorobenzyl)-4-(tert-butyl)benzamide (55 mg, 0.08 mmol) was dissolved in 1 mL of dichloromethane.
- Trifluoroacetic acid (420 ⁇ L, 5.646 mmol) was added dropwise under ice bath conditions, and stirred at room temperature for 7 h. Add NaOH under ice bath conditions Adjust the pH of the aqueous solution to 7-8 and stir at room temperature for 1.5 hours.
- N-(4-(5-(1-acryloylpiperidin-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2 ,3-d]pyrimidin-4-yl)-2-fluorobenzyl)-4-(tert-butyl)benzamide (40mg, 0.06mmol) was dissolved in 1mL dichloromethane, and three drops of Fluoroacetic acid (400 ⁇ L, 5.4 mmol), stirred at room temperature for 7 h. Add NaOH aqueous solution under ice bath conditions to adjust the pH to 7-8, and stir at room temperature for 1.5 hours. Add water, extract three times with ethyl acetate, wash once with saturated sodium chloride solution, and dry over anhydrous sodium sulfate. Concentrate to obtain 23 mg of white solid, yield 71.04%, melting point 154-155°C.
- N-(4-(5-(1-(but-2-ynyl)piperidin-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)- 7H-pyrrolo[2,3-d]pyrimidin)-4-yl)benzyl)-4-(tert-butyl)benzamide (75 mg, 0.113 mmol) was dissolved in 1.5 mL dichloromethane in an ice bath. Trifluoroacetic acid (760 ⁇ L, 10.2 mmol) was added dropwise at room temperature, and stirred at room temperature for 7 h. Add NaOH aqueous solution under ice bath conditions to adjust the pH to 7-8, and stir at room temperature for 1.5 hours. Add water, extract three times with ethyl acetate, wash once with saturated sodium chloride solution, and dry over anhydrous sodium sulfate. Concentrate to obtain 43 mg of white solid, yield 71.30%, melting point 156-157°C.
- N-(4-(5-(1-acryloylpiperidin-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2 ,3-d]pyrimidin-4-yl)benzyl)-4-(tert-butyl)benzamide 64mg, 0.1mmol was dissolved in 1.5mL methylene chloride, and trifluoroacetic acid ( 670 ⁇ L, 9 mmol), stirred at room temperature for 7 h. Add NaOH aqueous solution under ice bath conditions to adjust the pH to 7-8, and stir at room temperature for 1.5 hours. Add water, extract three times with ethyl acetate, wash once with saturated sodium chloride solution, and dry over anhydrous sodium sulfate. Concentrate to obtain 37 mg of white solid, with a yield of 70.92%.
- N-(4-(5-(1-(but-2-ynyl)piperidin-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)- 7H-pyrrolo[2,3-d]pyrimidin)-4-yl)-2-methylbenzyl)-4-(tert-butyl)benzamide (68 mg, 0.1 mmol) was dissolved in 1.5 mL dichloromethane , add trifluoroacetic acid (670 ⁇ L, 9 mmol) dropwise under ice bath conditions, and stir at room temperature for 7 h. Add NaOH aqueous solution under ice bath conditions to adjust the pH to 7-8, and stir at room temperature for 1.5 hours. Add water, extract three times with ethyl acetate, wash once with saturated sodium chloride solution, and dry over anhydrous sodium sulfate. Concentrate to obtain 35 mg of white solid, yield 63.90%, melting point 162-163°C.
- N-(4-(5-(1-acryloylpiperidin-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2 ,3-d]pyrimidin-4-yl)-2-methylbenzyl)-4-(tert-butyl)benzamide (67mg, 0.1mmol) was dissolved in 1.5mL dichloromethane and dropped in an ice bath.
- trifluoroacetic acid (670 ⁇ L, 9 mmol) and stir at room temperature for 7 h.
- NaOH aqueous solution under ice bath conditions to adjust the pH to 7-8, and stir at room temperature for 1.5 hours.
- the reaction was cooled to room temperature, water was added, filtered under reduced pressure, the filtrate was collected, extracted three times with ethyl acetate, washed once with saturated sodium chloride solution, and dried over anhydrous sodium sulfate. Concentrate and separate by column chromatography.
- the experiment used the ADP-Glo TM detection kit from Promega Corporation. A total of 11 concentrations (10 ⁇ M to 1 nM) were set. Add 50 ⁇ L of compound to the 384-well dilution plate and use Echo to transfer 0.05 ⁇ L of the diluted compound solution per row into the 384 assay plate, containing 2 replicates per column. Add 2.5 ⁇ L of enzyme working solution to the 384-well assay plate and incubate with the compound at 25°C for 15 minutes. Add 2.5 ⁇ L of substrate working solution to initiate the reaction, and add 4 ⁇ L of ADP Glo reagent after 60 min. After 60 minutes, add 8 ⁇ L of kinase detection reagent and incubate at 25°C for 60 minutes. The luminescence signal was read using an envision Perkin Elmer plate reader (Envision, PE, USA).
- Inhibitory activity grading "A” means the IC 50 value is less than 10nM, “B” means the IC 50 value is between 10nM and 100nM, “C” means the IC 50 value is between 100nM and 1000nM, “D” means the IC50 value Greater than 1000nM.
- the experiment used an in vitro screening system in a 96-well plate. 95 ⁇ L of cell suspension was added to each well. Culture medium without cells (containing 0.1% DMSO) was added to the Min control well. Take 5 ⁇ L of 20 ⁇ compound working solution and add it to the cell culture plate. Add 5 ⁇ L of DMSO cell culture medium mixture to the Max control. The final DMSO concentration is 0.1%. Incubate the culture plate in a 37°C, 5% CO2 incubator for 72 hours.
- Cell viability was detected using CellTiter-Glo luminescence method. SpectraMax Paradigm readings yield the corresponding fluorescence value RLU for each well.
- Cell proliferation inhibition rate (Inhibition Rate) data is processed using the following formula:
- Inhibition Rate (Inh%) 100-(RLUDrug-RLUMin)/(RLUMax-RLUMin)*100%. Calculate the inhibition rates corresponding to different concentrations of compounds in EXCEL, and then use GraphPad Prism software to draw an inhibition rate curve and calculate relevant parameters. The parameters include the maximum and minimum inhibition rates of cells, and IC 50 values.
- Inhibitory activity grading "A” means the IC 50 value is less than 10nM, “B” means the IC 50 value is between 10nM and 100nM, “C” means the IC 50 value is between 100nM and 1000nM, “D” means the IC50 value Greater than 1000nM.
- mice Male BALB/c mice were selected and divided into oral administration group and intravenous injection group.
- oral administration group 10 mg/kg was administered orally, and blood was collected from the orbital venous plexus at 5 min, 10 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 12 h.
- intravenous injection group 2 mg/kg was administered intravenously, and blood was taken from the orbital venous plexus at 2 min, 5 min, 10 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 12 h.
- Plasma was prepared by centrifugation and a standard curve was established.
- Example 8 improves the problem of low bioavailability of BTK irreversible inhibitors.
- aPharmacokinetic parameters are the average of three experimental measurements.
- mice Female CB17SCID mice were selected, TMD8 cells were subcutaneously inoculated, and administration began in groups when the average tumor volume reached approximately 150-200mm3 .
- Ibrutinib was used as the positive control drug and was orally administered at a dose of 25 mg/kg; the compounds of the present invention were orally administered at a dose of 12.5 mg/kg, 25 mg/kg and 50 mg/kg respectively. Administration was given twice daily for 21 consecutive days.
- Example Compound 8 As shown in Figure 1, the low, medium and high dosage groups of Example Compound 8 all had an inhibitory effect on tumors, and the inhibitory effect of the high-dose group on tumors was equivalent to that of the positive drug ibrutinib.
- Compound 8 in the present invention exhibits strong anti-tumor activity in vivo and provides a new option for the treatment of diffuse large B lymphoma and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明涉及一类含吡咯并嘧啶类结构的化合物或其药学上可接受盐,其制备方法,含有该类化合物的药物组合物以及该类化合物的医药用途。本发明化合物具有特异性抑制BTK的作用,且对TMD-8淋巴瘤细胞抑制作用较强,具有较高的生物利用度且在TMD-8肿瘤模型上表现出了较强的抑制活性,能够用于制备治疗B细胞恶性肿瘤、自身免疫性疾病等与BTK功能相关的疾病的药物。
Description
本发明涉及药物领域,具体涉及一类含吡咯并嘧啶类结构的化合物或其药学上可接受的盐,其制备方法,含有该类化合物的药物组合物以及该类化合物在制备治疗与布鲁顿式酪氨酸激酶(Bruton’s tyrosine kinase,BTK)功能相关的疾病的药物中的应用。
酪氨酸蛋白激酶(Tyrosine protein kinase,TPK)是一类催化ATP上γ-磷酸转移到蛋白酪氨酸残基上的激酶,能催化多种底物蛋白质酪氨酸残基磷酸化,在细胞信号转导通路中占据了十分重要的作用,调节细胞生长、分化、死亡等一系列生理生化过程。酪氨酸蛋白激酶功能失调将引发生物体内一系列疾病。
BTK是酪氨酸蛋白激酶Tec家族的主要成员之一。BTK是B细胞抗原受体(B-cell receptor,BCR)信号转导通路中的关键激酶,在BCR信号通路中,磷酸化的PI3K(phosphatidylinositol 3-kinase)将膜上的PIP2转化为第二信使PIP3。PIP3结合到BTK的PH结构域,BTK随后会被募集到细胞膜,随后Tyr-551残基被SYK和LYN激酶磷酸化。BTK接着在Tyr-223残基进行自磷酸化反应从而具备生理活性。活化的BTK激活许多下游通路,如下游的蛋白激酶C,核因子kappa-B(NF-κB),MAPK通路等,对B细胞多个细胞过程,如生长、发育、分化、凋亡产生重要影响。
BTK在B细胞相关恶性肿瘤,如急性B淋巴细胞白血病,非霍奇金性淋巴瘤,在自身免疫性疾病,如类风湿关节炎、系统性红斑狼疮等疾病中扮演着重要的角色。这使得BTK成为B细胞恶性肿瘤和自身免疫性疾病的潜在靶点。现有BTK抑制剂选择性差,生物利用度低,导致临床用药量较大,毒副作用较大。因此,亟需发现活性高,成药性好的新型BTK抑制剂。
发明内容
本发明提供了一类含吡咯并嘧啶类结构的化合物或其药学上可接受的盐,其制备方法,含有该类化合物的药物组合物以及该类化合物在制备治疗与BTK功能相关的疾病的药物中的应用。
为解决本发明的技术问题,本发明提供如下技术方案:
本发明技术方案的第一方面是提供如通式(I)所示的化合物或其药学上可接受的盐:
其中,R选自且R3选自丙烯酰基,2-丁炔酰基;
R1,R2取代基为一个或多个,选自H,C1-8直链或支链烷基,C3-8环烷基,C1-8烷氧基,C1-8烷基氨基,卤素,羟基,氨基,氰基,且所述的C1-8直链或支链烷基进一步被一个或多个卤素,羟基,氨基或氰基取代。
进一步地,根据权利要求1的化合物或其药学上可接受的盐,其特征在于R1,R2选自H,甲基,乙基,正丙基,异丙基,正丁基,异丁基,叔丁基,正戊基,异戊基,环丙基,环丁基,环戊基,甲氧基,乙氧基,丙氧基,甲基氨基,乙基氨基,F,Cl,Br,I,羟基,氨基,氰基,或者选自被一个或多个卤素取代的甲基,乙基,正丙基,异丙基,正丁基,异丁基,叔丁基,正戊基,异戊基。
进一步地,根据权利要求1的化合物或其药学上可接受的盐,其特征在于R1选自H,甲基,乙基,三氟甲基,F,Cl,Br,或I;R2选自H,异丙基,异丁基,叔丁基,异戊基,环丙基,环丁基、环戊基。
所述药学上可接受的盐选自有机酸盐或无机酸盐,包括但不限于盐酸盐,氢溴酸盐,硫酸盐,磷酸盐,醋酸盐,柠檬酸盐,苹果酸盐,富马酸盐,酒石酸盐或甲磺酸盐。
作为本发明的优选方案,通式(I)的化合物具有如下的结构:
本发明技术方案的另一方面是提供如通式(I)所示的化合物或其药学上可接受的盐的合成方法,其合成路线如下:
路线(1):
试剂与条件:(a)(2-(氯甲氧基)乙基)三甲基硅烷,碳酸钾,N,N-二甲基甲酰胺,室温;(b)N-Boc-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯,1,1'-二(二苯膦基)二茂铁二氯化钯,碳酸钾,1,4-二氧六环,100℃;(c)R1,R2取代苯基硼酸频哪醇酯,1,1'-二(二苯膦基)二茂铁二氯化钯,碳酸钾,1,4-二氧六环,100℃;(d)盐酸的乙醇溶液,室温;丙烯酰氯,N,N-二异丙基乙胺,二氯甲烷,室温;(e)三氟乙酸,二氯甲烷,室温;四氢呋喃溶液,氢氧化钠溶液,室温;
路线(2):
试剂与条件:(a)(2-(氯甲氧基)乙基)三甲基硅烷,碳酸钾,N,N-二甲基甲酰胺,室温;(b)N-Boc-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯,1,1'-二(二苯膦基)二茂铁二氯化钯,碳酸钾,1,4-二氧六环,100℃;(c)R1,R2取代苯基硼酸频哪醇酯,1,1'-二(二苯膦基)二茂铁二氯化钯,碳酸钾,1,4-二氧六环,100℃;(d)氢气,钯碳,乙酸乙酯溶液,甲醇溶液,室温(e)盐酸的乙醇溶液,室温;丙烯酰氯,N,N-二异丙基乙胺,二氯甲烷,室温;(f)三氟乙酸,二氯甲烷,室温;四氢呋喃溶液,氢氧化钠溶液,室温;
其中R1、R2的定义同前所述。
本发明技术方案的另一方面是提供药物组合物,其特征在于,所述药物组合物中包含
前述的化合物或其药学上可接受的盐以及药学上可接受的载体。
本发明技术方案的另一方面是提供如通式(I)所示的化合物或其药学上可接受的盐在制备治疗与BTK功能相关的疾病的药物中的应用。
本发明技术方案的另一方面是提供如通式(I)所示的化合物或其药学上可接受的盐在制备治疗类风湿性关节炎,系统性红斑狼疮的药物中的应用。
本发明技术方案的另一方面是提供如通式(I)所示的化合物或其药学上可接受的盐在制备治疗非霍奇金性淋巴瘤的药物中的用途,所述的非霍奇金性淋巴瘤优选套细胞淋巴瘤,弥漫大B细胞淋巴瘤。
本发明技术方案的另一方面是提供如通式(I)所示的化合物或其药学上可接受的盐在制备治疗华式巨球蛋白血症,慢性淋巴细胞白血病或原发性中枢神经系统淋巴瘤药物中的用途。
有益技术效果
本发明技术方案中的所有实施例化合物均对BTK有明显的抑制活性,对TMD-8淋巴瘤细胞均有明显的抑制作用,且实施例8有较高的口服生物利用度,优于上市药物依鲁替尼,并在TMD-8动物模型上展现了较强的肿瘤抑制活性,展现了良好的成药前景。
图1化合物的体内抑瘤效果。(A)小鼠体重-时间曲线;(B)肿瘤体积-时间曲线;(C)瘤重-剂量图;(D)各组肿瘤的照片
实施例1
N-(4-(5-(1-(丁-2-炔酰基)-1,2,3,6-四氢吡啶-4-基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)-4-(叔丁基)苯甲酰胺
(1)N-(4-溴-2-氟苄基)-4-(叔丁基)苯甲酰胺的制备
将2-氟-4-溴苄胺(214mg,1mmol)加入瓶中,用2mL二氯甲烷溶解,加入二异丙基乙胺(194μL,1.1mmol),搅拌均匀,冰浴条件下,滴加4-叔丁基苯甲酰氯(205μL,1.05mmol),室温搅拌1.5h。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=10:1,得白色固体331mg,收率90.93%,熔点101-102℃。
1H NMR(400MHz,Chloroform-d)δ7.74–7.68(m,2H),7.46–7.41(m,2H),7.32–7.27(m,1H),7.25–7.24(m,1H),7.23(dt,J=3.3,1.3Hz,1H),6.59(s,1H),4.62(d,J=5.9Hz,2H),1.32(s,9H).
MS(ESI)m/z 364.07(M+H)+.
(2)4-(叔丁基)-N-(2-氟-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苄基)苯甲酰胺的制备
将N-(4-溴-2-氟苄基)-4-(叔丁基)苯甲酰胺(4.0572g,0.011mol),联硼酸频那醇酯(4.2499g,0.0165mol)和醋酸钾(3.2849g,0.033mol)加入瓶中,加入40mL二氧六环,室温搅拌均匀,加入Pd(dppf)Cl2(0.8164g,0.0011mol),氩气保护下加热至100℃反应6h。将反应冷却至室温,加水,减压抽滤,收集滤液,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=5:1,得白色固体2.38g,收率52.73%,熔点110-111℃
1H NMR(400MHz,Chloroform-d)δ7.73–7.69(m,2H),7.54(dd,J=7.4,1.1Hz,1H),7.47(dd,J=10.4,1.1Hz,1H),7.44(d,J=2.0Hz,1H),7.42(d,J=1.9Hz,1H),7.39(d,J=7.4Hz,1H),6.53(d,J=5.0Hz,1H),4.70(d,J=5.8Hz,2H),1.33(d,J=4.5Hz,21H).
MS(ESI)m/z 412.25(M+H)+.
(3)4-氯-5-碘-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶的制备
将4-氯-5-碘-7H-吡咯并[2,3-d]嘧啶(7g,0.025mol)加入瓶中,用45mL DMF溶解,加
入碳酸钾(10.3658g,0.075mol),室温搅拌0.5h,然后冰浴条件下滴加SEMCl(6.6mL,0.0375mol),室温搅拌6h。加水,减压抽滤,收集滤饼,柱层析分离,洗脱剂为石油醚:乙酸乙酯=10:1,得白色固体7.92g,收率77.34%,熔点90-91℃
1H NMR(500MHz,DMSO-d6)δ8.70(s,1H),8.15(s,1H),5.61(s,2H),3.52(t,J=8.0Hz,2H),0.82(t,J=8.0Hz,2H),-0.09(s,9H).
MS(ESI)m/z 410.99(M+H)+.
(4)4-(4-氯)叔丁基-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐的制备
将4-氯-5-碘-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶(1.2406g,3.0278mmol),4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)-3,6-二氢吡啶-1(2H)-羧酸叔丁酯(0.9652g,3.0278mmol)和碳酸钾(0.8357g,6.0556mmol)加入瓶中,加入12mL二氧六环和6mL水,室温搅拌均匀,加入Pd(dppf)Cl2(0.2215g,0.30278mmol),氩气保护下加热至100℃反应2h。将反应冷却至室温,加水,减压抽滤,收集滤液,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=5:1,得浅黄色固体1.01g,收率71.63%,熔点75-76℃
1H NMR(500MHz,DMSO-d6)δ8.66(s,1H),7.79(s,1H),5.83(s,1H),5.61(s,2H),3.99(s,2H),3.61–3.49(m,4H),2.44(s,2H),1.43(s,9H),0.82(t,J=8.0Hz,2H),-0.11(s,9H).
MS(ESI)m/z 465.21(M+H)+.
(5)叔丁基4-(4-(4-((4-(叔丁基)苯甲酰氨基)甲基)-3-氟苯基)-7-((2-(三甲基甲硅烷基)乙氧基)
甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐的制备
将4-(4-氯)叔丁基-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(500mg,1.075mmol),4-(叔丁基)-N-(2-氟-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苄基)苯甲酰胺(663mg,1.6125mmol)和碳酸钾(297mg,
2.15mmol)加入瓶中,加入5mL二氧六环和2.5mL水,室温搅拌均匀,加入Pd(dppf)Cl2(78mg,0.1075mmol),氩气保护下加热至100℃反应7h。将反应冷却至室温,加水,减压抽滤,收集滤液,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=5:1,得浅黄色固体360mg,收率46.94%,熔点85-86℃。
1H NMR(400MHz,DMSO-d6)δ9.01(t,J=5.7Hz,1H),8.91(s,1H),7.87–7.81(m,2H),7.77(s,1H),7.51–7.45(m,4H),7.41(d,J=10.9Hz,1H),5.65(s,2H),5.39–5.27(m,1H),4.59(d,J=5.8Hz,2H),3.73(s,2H),3.60–3.54(m,2H),3.21(t,J=5.6Hz,2H),1.94(s,2H),1.40(s,9H),1.30(s,9H),0.84(dd,J=8.5,7.5Hz,2H),-0.09(s,9H).
MS(ESI)m/z 714.38(M+H)+.
(6)N-(4-(5-(1-(丁-2-炔酰基)-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-)吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)-4-(叔丁基)苯甲酰胺的制备
将叔丁基4-(4-(4-((4-(叔丁基)苯甲酰氨基)甲基)-3-氟苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(125mg,0.175mmol)加入瓶中,加入0.75mL无水乙醇,室温搅拌均匀,滴加浓盐酸(438μL,5.2mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥,浓缩得油状物。将油状物溶于1.5mL二氯甲烷,在冰盐浴的条件下加入DIEA(96μL,0.54mmol)和NaOH(10mg,0.25mmol),滴加2-丁炔酰氯(28μL,0.324mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得白色固体42mg,收率34.43%,熔点90-91℃。
1H NMR(400MHz,DMSO-d6)δ8.99(dt,J=11.9,5.8Hz,1H),8.92(s,1H),7.84(dd,J=8.4,5.8Hz,2H),7.78(d,J=8.0Hz,1H),7.48(dd,J=9.8,3.3Hz,3H),7.45–7.38(m,2H),5.66(s,2H),5.34(s,1H),4.59(d,J=5.8Hz,2H),4.05(s,1H),3.83(s,1H),3.58(t,J=7.9Hz,2H),3.53(t,J=5.7Hz,1H),3.37(t,J=5.8Hz,1H),2.04(s,1H),2.00(s,3H),1.94(s,1H),1.30(s,9H),0.88–0.81(m,2H),-0.08(s,9H).
MS(ESI)m/z 680.35(M+H)+.
(7)标题化合物的制备
将N-(4-(5-(1-(丁-2-炔酰基)-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-)吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)-4-(叔丁基)苯甲酰胺(36mg,0.053mmol)溶于600μL二氯甲烷,在冰浴条件下滴加三氟乙酸(280μL,3.71mmol),室温搅拌7h。在冰浴条件下加入NaOH水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得黄色固体20mg,收率68.96%,熔点161-162℃。1H NMR(400MHz,DMSO-d6)δ12.33(s,1H),8.98(s,1H),8.83(s,1H),7.84(s,2H),7.58(s,1H),7.47(s,3H),7.42(s,2H),5.30(s,1H),4.59(d,J=5.7Hz,2H),4.03(d,J=10.2Hz,1H),3.82(s,1H),3.52(t,J=5.6Hz,1H),2.04(s,1H),1.99(s,3H),1.95(s,1H),1.30(s,9H).
HRMS calcd.For C33H33O2N5F(M+H)+550.2613,found 550.2653.
实施例2
N-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)-4-(叔丁基)苯甲酰胺
(1)N-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-)d]嘧啶-4-基)-2-氟苄基)-4-(叔丁基)苯甲酰胺的制备
将叔丁基4-(4-(4-((4-(叔丁基)苯甲酰氨基)甲基)-3-氟苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(125mg,0.175mmol)加入瓶中,加入0.75mL无水乙醇,室温搅拌均匀,滴加浓盐酸(438μL,5.2mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥,浓缩得油状物。将油状物溶于1.5mL二氯甲烷,在冰盐浴的条件下加入DIEA(192μL,1.08mmol)和NaOH(10mg,0.25mmol),滴加丙烯酰氯(33μL,0.405mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸
钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得白色固体64mg,收率53.23%,熔点155-158℃。
1H NMR(400MHz,DMSO-d6)δ9.01–8.90(m,1H),8.86(s,1H),7.82–7.68(m,3H),7.45–7.38(m,4H),7.37–7.31(m,1H),6.65(dd,J=16.7,10.4Hz,1H),6.06(dd,J=15.7,11.4Hz,1H),5.60(d,J=8.3Hz,3H),5.27(d,J=72.6Hz,1H),4.52(d,J=5.7Hz,2H),3.90–3.80(m,2H),3.52(t,J=7.9Hz,2H),3.44–3.30(m,2H),1.92(d,J=12.0Hz,2H),1.24(s,9H),0.79(t,J=7.9Hz,2H),-0.14(s,9H).
MS(ESI)m/z 668.34(M+H)+.
(2)标题化合物的制备
将N-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-)d]嘧啶-4-基)-2-氟苄基)-4-(叔丁基)苯甲酰胺(35mg,0.053mmol)溶于600μL二氯甲烷,在冰浴条件下滴加三氟乙酸(280μL,3.71mmol),室温搅拌7h。在冰浴条件下加入NaOH水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得黄色固体23mg,收率80.72%,熔点179-180℃。1H NMR(400MHz,DMSO-d6)δ12.39(s,1H),9.09(s,1H),8.82(s,1H),7.85(d,J=7.4Hz,2H),7.59(d,J=20.0Hz,1H),7.51–7.34(m,5H),6.69(dd,J=16.6,10.5Hz,1H),6.21–5.99(m,1H),5.65(t,J=10.2Hz,1H),5.27(d,J=83.4Hz,1H),4.57(d,J=5.4Hz,2H),3.90(s,2H),3.45(s,1H),3.37(s,1H),2.03(s,1H),1.95(s,1H),1.29(s,9H).
HRMS calcd.For C32H33O2N5F(M+H)+538.2613,found 538.2611.
实施例3
N-(4-(5-(1-(丁-2-炔酰基))-1,2,3,6-四氢吡啶-4-基)-7H-吡咯并[2,3-d]嘧啶-4-基)苄基)-4-(叔丁基)苯甲酰胺
(1)N-(4-溴苄基)-4-(叔丁基)苯甲酰胺的制备
将4-溴苄胺(1g,5.375mmol)加入瓶中,用20mL二氯甲烷溶解,加入二异丙基乙胺
(1mL,5.9125mmol),搅拌均匀,冰浴条件下,滴加4-叔丁基苯甲酰氯(1.125mL,5.64375mmol),室温搅拌3h。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=10:1,得白色固体1.8g,收率96.72%,熔点110-111℃。
1H NMR(400MHz,Chloroform-d)δ7.75–7.70(m,2H),7.48–7.42(m,4H),7.24–7.19(m,2H),6.43(s,1H),4.59(d,J=5.7Hz,2H),1.33(s,9H).
MS(ESI)m/z 346.98(M+H)+.
(2)4-(叔丁基)-N-(4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苄基)苯甲酰胺的制备
将N-(4-溴苄基)-4-(叔丁基)苯甲酰胺(1.77g,5.112mmol),联硼酸频那醇酯(1.9472g,7.668mmol)和醋酸钾(1.5051g,15.336mmol)加入瓶中,加入20mL二氧六环,室温搅拌均匀,加入Pd(dppf)Cl2(0.374g,0.5112mmol),氩气保护下加热至100℃反应6h。将反应冷却至室温,加水,减压抽滤,收集滤液,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=5:1,得白色固体1.01g,收率50.39%,熔点131-132℃。
1H NMR(400MHz,Chloroform-d)δ7.82–7.77(m,2H),7.75–7.69(m,2H),7.47–7.41(m,2H),7.38–7.32(m,2H),6.36(s,1H),4.68–4.65(m,2H),1.34(s,12H),1.33(s,9H).
MS(ESI)m/z 394.24(M+H)+.
(3)叔丁基4-(4-(4-((4-(叔丁基)苯甲酰胺基)甲基)苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐的制备
将4-(4-氯)叔丁基-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(500mg,1.075mmol),4-(叔丁基)-N-(4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苄基)苯甲酰胺(634mg,1.6125mmol)和碳酸钾(297mg,2.15mmol)加入瓶中,加入5mL二氧六环和2.5mL水,室温搅拌均匀,加入Pd(dppf)Cl2(78mg,
0.1075mmol),氩气保护下加热至100℃反应10h。将反应冷却至室温,加水,减压抽滤,收集滤液,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=5:1,得白色固体610mg,收率81.55%,熔点161-162℃。
1H NMR(500MHz,DMSO-d6)δ9.01(d,J=5.4Hz,1H),8.88(s,1H),7.84(d,J=8.0Hz,2H),7.72(s,1H),7.61(d,J=7.8Hz,2H),7.48(d,J=8.0Hz,2H),7.44(d,J=8.0Hz,2H),5.65(s,2H),5.34(s,1H),4.56(d,J=5.9Hz,2H),3.72(s,2H),3.58(t,J=7.9Hz,2H),3.16(t,J=5.7Hz,2H),1.88(s,2H),1.40(s,9H),1.30(s,9H),0.84(t,J=8.0Hz,2H),-0.06–-0.10(m,9H).MS(ESI)m/z 696.35(M+H)+.
(4)N-(4-(5-(1-(丁-2-炔酰基)-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-)吡咯并[2,3-d]嘧啶-4-基)苄基)-4-(叔丁基)苯甲酰胺的制备
将叔丁基4-(4-(4-((4-(叔丁基)苯甲酰胺基)甲基)苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(150mg,0.216mmol)加入瓶中,加入0.9mL无水乙醇,室温搅拌均匀,滴加浓盐酸(525μL,6.24mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥,浓缩得油状物。将油状物溶于2mL二氯甲烷,在冰盐浴的条件下加入DIEA(115μL,0.648mmol)和NaOH(12mg,0.3mmol),滴加2-丁炔酰氯(34μL,0.389mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得白色固体57mg,收率40.21%,
熔点95-96℃。
1H NMR(500MHz,DMSO-d6)δ8.96(dt,J=11.7,6.0Hz,1H),8.87(s,1H),7.82(t,J=7.6Hz,2H),7.70(d,J=7.4Hz,1H),7.57(t,J=6.5Hz,2H),7.46(d,J=8.0Hz,2H),7.41(t,J=7.0Hz,2H),5.63(s,2H),5.33(s,1H),4.55(d,J=5.8Hz,2H),4.03(s,1H),3.81(s,1H),3.56(t,J=8.0Hz,2H),3.46(t,J=5.4Hz,1H),3.30(s,1H),1.99(d,J=28.1Hz,3H),1.90(s,1H),1.83(s,1H),1.28(d,J=2.2Hz,9H),0.82(t,J=7.9Hz,2H),-0.11(s,9H).
MS(ESI)m/z 662.3497(M+H)+.
(5)标题化合物的制备
将N-(4-(5-(1-(丁-2-炔酰基)-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-)吡咯并[2,3-d]嘧啶-4-基)苄基)-4-(叔丁基)苯甲酰胺(85mg,0.1277mmol)溶于1.5mL二氯甲烷,在冰浴条件下滴加三氟乙酸(664μL,8.939mmol),室温搅拌7h。在冰浴条件下加入NaOH水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得黄色固体60mg,收率88.37%,熔点139-140℃1H NMR(400MHz,DMSO-d6)δ12.27(s,1H),9.04–8.94(m,1H),8.81(s,1H),7.86–7.81(m,2H),7.59(dd,J=8.1,3.8Hz,2H),7.55(dd,J=7.3,2.4Hz,1H),7.48(d,J=8.5Hz,2H),7.42(dd,J=8.1,4.4Hz,2H),5.31(d,J=3.2Hz,1H),4.56(d,J=5.9Hz,2H),4.04(s,1H),3.85–3.78(m,1H),3.48(t,J=5.6Hz,1H),2.04(s,1H),1.98(s,3H),1.93(s,1H),1.30(s,9H).
HRMS calcd.For C33H34O2N5(M+H)+532.2707,found 532.2696.
实施例4
N-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基))-7H-吡咯并[2,3-d]嘧啶-4-基)苄基)-4-(叔丁基)苯甲酰胺
(1)N-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-)d]嘧啶-4-基)苄基)-4-(叔丁基)苯甲酰胺的制备
将叔丁基4-(4-(4-((4-(叔丁基)苯甲酰胺基)甲基)苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(150mg,0.216mmol)加入瓶中,加入0.9mL无水乙醇,室温搅拌均匀,滴加浓盐酸(525μL,6.24mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥,浓缩得油状物。将油状物溶于2mL二氯甲烷,在冰盐浴的条件下加入DIEA(230μL,1.296mmol)和NaOH(12mg,0.3mmol),滴加丙烯酰氯(39.6μL,
0.486mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得白色固体68mg,收率48.52%,
熔点71-72℃。
1H NMR(500MHz,DMSO-d6)δ9.01–8.93(m,1H),8.86(s,1H),7.81(d,J=7.9Hz,2H),7.71(d,J=22.4Hz,1H),7.57(t,J=8.7Hz,2H),7.44(d,J=7.9Hz,2H),7.39(t,J=9.0Hz,2H),6.65(dd,J=17.1,10.5Hz,1H),6.16–6.03(m,1H),5.70–5.58(m,3H),5.28(d,J=105.0Hz,1H),4.52(d,J=5.9Hz,2H),3.88(d,J=3.3Hz,2H),3.55(t,J=7.9Hz,2H),3.39(t,J=5.3Hz,1H),3.31(t,J=4.6Hz,1H),1.94(s,1H),1.86(s,1H),1.27(s,9H),0.82(t,J=7.9Hz,2H),-0.11(s,9H).
MS(ESI)m/z 650.38(M+H)+.
(2)标题化合物的制备
将N-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-)d]嘧啶-4-基)苄基)-4-(叔丁基)苯甲酰胺(83mg,0.1277mmol)溶于1.5mL二氯甲烷,在冰浴条件下滴加三氟乙酸(664μL,8.939mmol),室温搅拌7h。在冰浴条件下加入NaOH水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得白色固体62mg,收率93.43%,熔点132-133℃。1H NMR(500MHz,DMSO-d6)δ12.26(s,1H),9.04–8.97(m,1H),8.80(s,1H),7.83(d,J=8.3Hz,2H),7.61–7.51(m,3H),7.50–7.44(m,2H),7.40(t,J=9.4Hz,2H),6.75–6.62(m,1H),6.11(dd,J=22.8,14.8Hz,1H),5.66(dd,J=25.7,11.4Hz,1H),5.26(d,J=113.8Hz,1H),4.57–4.52(m,2H),3.89(s,2H),3.45–3.40(m,1H),3.33(t,J=5.2Hz,1H),1.99(s,1H),1.89(s,1H),1.30(s,9H).
HRMS calcd.For C32H34O2N5(M+H)+520.2707,found 520.2746.
实施例5
N-(4-(5-(1-(丁-2-炔酰基))-1,2,3,6-四氢吡啶-4-基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-甲基苄基)-4-(叔丁基)苯甲酰胺
(1)N-(4-溴-2-甲基苄基)-4-(叔丁基)苯甲酰胺的制备
将2-甲基-4-溴苄胺(200mg,1mmol)加入瓶中,用2mL二氯甲烷溶解,加入二异丙基乙胺(194μL,1.1mmol),搅拌均匀,冰浴条件下,滴加4-叔丁基苯甲酰氯(205μL,1.05mmol),室温搅拌1.5h。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=10:1,得白色固体333mg,收率92.55%,熔点125-126℃。
1H NMR(400MHz,Chloroform-d)δ7.79–7.63(m,2H),7.49–7.37(m,2H),7.29(ddt,J=19.4,11.5,4.5Hz,2H),7.13(d,J=8.2Hz,1H),6.29(s,1H),4.55(d,J=5.5Hz,2H),2.31(s,3H),1.31(s,9H).
MS(ESI)m/z 361.06(M+H)+.
(2)4-(叔丁基)-N-(2-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苄基)苯甲酰胺的制备
将N-(4-溴-2-甲基苄基)-4-(叔丁基)苯甲酰胺(1.84g,5.112mmol),联硼酸频那醇酯(1.9472g,7.668mmol)和醋酸钾(1.5051g,15.336mmol)加入瓶中,加入20mL二氧六环,室温搅拌均匀,加入Pd(dppf)Cl2(0.374g,0.5112mmol),氩气保护下加热至100℃反应6h。将反应冷却至室温,加水,减压抽滤,收集滤液,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=5:1,得白色固体1.02g,收率48.87%,熔点133-134℃。
1H NMR(400MHz,Chloroform-d)δ7.71–7.67(m,2H),7.65–7.59(m,2H),7.45–7.40(m,2H),7.29(d,J=7.5Hz,1H),6.20(s,1H),4.64(d,J=5.3Hz,2H),2.35(s,3H),1.33(s,12H),1.31(s,9H).
MS(ESI)m/z 408.27(M+H)+.
(3)叔丁基4-(4-(4-((4-(叔丁基)苯甲酰胺基)甲基)-3-甲基苯基)-7-((2-(三甲基甲硅烷基))乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐的制备
将4-(4-氯)叔丁基-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(500mg,1.075mmol),4-(叔丁基)-N-(2-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苄基)苯甲酰胺(656mg,1.6125mmol)和碳酸钾(297mg,2.15mmol)加入瓶中,加入5mL二氧六环和2.5mL水,室温搅拌均匀,加入Pd(dppf)Cl2(78mg,0.1075mmol),氩气保护下加热至100℃反应10h。将反应冷却至室温,加水,减压抽滤,收集滤液,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=5:1,得白色固体524mg,收率68.65%,熔点86-87℃。
1H NMR(400MHz,DMSO-d6)δ8.94–8.89(m,1H),8.88(s,1H),7.85(d,J=8.2Hz,2H),7.74(s,1H),7.53(d,J=7.7Hz,1H),7.49(d,J=8.2Hz,2H),7.41(s,1H),7.38(d,J=7.9Hz,1H),5.65(s,2H),5.34(s,1H),4.53(d,J=5.7Hz,2H),3.72(s,2H),3.57(t,J=7.9Hz,2H),3.17(t,J=5.6Hz,2H),2.38(s,3H),1.90(s,2H),1.40(s,9H),1.30(s,9H),0.85(dd,J=10.0,5.9Hz,2H),-0.09(s,9H).
MS(ESI)m/z 710.41(M+H)+.
(4)N-(4-(5-(1-(丁-2-炔酰基)-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-)吡咯并[2,3-d]嘧啶-4-基)-2-甲基苄基)-4-(叔丁基)苯甲酰胺的制备
将叔丁基4-(4-(4-((4-(叔丁基)苯甲酰胺基)甲基)-3-甲基苯基)-7-((2-(三甲基甲硅烷基))乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(153mg,0.216mmol)加入瓶中,加入0.9mL无水乙醇,室温搅拌均匀,滴加浓盐酸(525μL,6.24mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥,浓缩得油状物。将油状物溶于2mL二氯甲烷,在冰盐浴的条件下加入DIEA(115μL,0.648mmol)和NaOH(12mg,0.3mmol),滴加2-丁炔酰氯(34μL,
0.389mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得白色固体130mg,收率89.04%,熔点84-85℃。
1H NMR(500MHz,DMSO-d6)δ8.89–8.78(m,2H),7.82(t,J=7.9Hz,2H),7.70(d,J=13.2Hz,1H),7.44(dd,J=10.3,7.7Hz,3H),7.34(dd,J=19.6,8.2Hz,2H),5.61(s,2H),5.31(s,1H),4.50(d,J=5.7Hz,2H),4.01(s,1H),3.86–3.70(m,1H),3.54(t,J=7.9Hz,2H),3.47(t,J=5.7Hz,1H),3.31(d,J=11.5Hz,1H),2.34(d,J=4.4Hz,3H),1.99(d,J=29.7Hz,3H),1.89(d,J=14.7Hz,2H),1.27(s,9H),0.81(d,J=6.4Hz,2H),-0.12(s,9H).
MS(ESI)m/z 676.36(M+H)+.
(5)标题化合物的制备
将N-(4-(5-(1-(丁-2-炔酰基)-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-)吡咯并[2,3-d]嘧啶-4-基)-2-甲基苄基)-4-(叔丁基)苯甲酰胺(86mg,0.1277mmol)溶于1.5mL二氯甲烷,在冰浴条件下滴加三氟乙酸(664μL,8.939mmol),室温搅拌7h。在冰浴条件下加入NaOH水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得白色固体59mg,收率84.67%,熔点162-163℃。
1H NMR(400MHz,DMSO-d6)δ12.21(s,1H),8.87–8.78(m,1H),8.75(s,1H),7.81(dd,J=8.3,6.0Hz,2H),7.51(d,J=12.2Hz,1H),7.43(t,J=8.7Hz,3H),7.32(dd,J=17.7,8.5Hz,2H),5.24(d,J=9.6Hz,1H),4.48(d,J=5.6Hz,2H),3.98(s,1H),3.78(s,1H),3.45(t,J=5.4Hz,1H),3.30(d,J=4.9Hz,1H),2.32(s,3H),1.94(s,2H),1.90(s,3H),1.26(s,9H).
HRMS calcd.For C34H36O2N5(M+H)+546.2864,found 546.2859.
实施例6
N-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-甲基苄基)-4-(叔丁基)苯甲酰胺
(1)N-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-)d]嘧啶-4-基)-2-甲基苄基)-4-(叔丁基)苯甲酰胺的制备
将叔丁基4-(4-(4-((4-(叔丁基)苯甲酰胺基)甲基)-3-甲基苯基)-7-((2-(三甲基甲硅烷基))乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(153mg,0.216mmol)加入瓶中,加入0.9mL无水乙醇,室温搅拌均匀,滴加浓盐酸(525μL,6.24mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥,浓缩得油状物。将油状物溶于2mL二氯甲烷,在冰盐浴的条件下加入DIEA(230μL,1.296mmol)和NaOH(12mg,0.3mmol),滴加丙烯酰氯(39.6μL,0.486mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得白色固体98mg,收率68.33%,熔点90-91℃。
1H NMR(500MHz,DMSO-d6)δ8.88(s,2H),7.85(d,J=8.0Hz,2H),7.75(d,J=17.1Hz,1H),7.48(t,J=6.5Hz,3H),7.41(s,1H),7.35(d,J=7.4Hz,1H),6.70(dt,J=16.5,10.7Hz,1H),6.12(t,J=19.2Hz,1H),5.65(s,3H),5.35(d,J=79.3Hz,1H),4.51(d,J=5.7Hz,2H),3.92(d,J=10.1Hz,2H),3.57(t,J=8.0Hz,2H),3.44–3.35(m,2H),2.35(s,3H),1.96(s,1H),1.90(s,1H),1.30(s,10H),0.86–0.82(m,2H),-0.09(s,9H).
MS(ESI)m/z 664.37(M+H)+.
(2)标题化合物的制备
将N-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-)d]嘧啶-4-基)-2-甲基苄基)-4-(叔丁基)苯甲酰胺(85mg,0.1277mmol)溶于1.5mL二氯甲烷,在冰浴条件下滴加三氟乙酸(664μL,8.939mmol),室温搅拌7h。在冰浴条件下加入NaOH水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得白色固体50mg,收率73.37%,熔点165-166℃。
1H NMR(400MHz,DMSO-d6)δ12.21(d,J=9.9Hz,1H),8.84(t,J=5.5Hz,1H),8.74(s,1H),7.79(d,J=8.0Hz,2H),7.51(d,J=13.6Hz,1H),7.42(d,J=7.2Hz,3H),7.35(s,1H),7.29(d,J=7.3Hz,1H),6.64(dt,J=16.6,9.4Hz,1H),6.06(t,J=16.2Hz,1H),5.60(t,J=9.4Hz,1H),5.24(d,J=68.0Hz,1H),4.46(d,J=5.7Hz,2H),3.85(s,2H),3.36(s,1H),3.11(s,1H),2.30(s,3H),1.89(d,J=28.3Hz,2H),1.24(s,9H).
HRMS calcd.For C33H36O2N5(M+H)+534.2864,found 534.2849.
实施例7
N-(4-(5-(1-(丁-2-炔酰基)-1,2,3,6-四氢吡啶)-4-基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)苯甲酰胺
(1)N-(4-溴-2-氟苄基)苯甲酰胺的制备
将2-氟-4-溴苄胺(700mg,3.43mmol)加入瓶中,用5mL二氯甲烷溶解,加入二异丙基乙胺(660μL,3.773mmol),搅拌均匀,冰浴条件下,滴加苯甲酰氯(410μL,3.6mmol),室温搅拌6.5h。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=10:1,得白色固体982mg,收率92.90%,熔点78-79℃。
1H NMR(400MHz,DMSO-d6)δ9.04(t,J=5.8Hz,1H),7.92–7.85(m,2H),7.57–7.51(m,2H),7.50–7.44(m,2H),7.40(dd,J=8.2,1.9Hz,1H),7.32(t,J=8.1Hz,1H),4.47(d,J=5.8Hz,2H).
MS(ESI)m/z 308.01(M+H)+.
(2)N-(2-氟-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苄基)苯甲酰胺的制备
将N-(4-溴-2-氟苄基)苯甲酰胺(982mg,3.18676mmol),联硼酸频那醇酯(1.214g,4.78mmol)和醋酸钾(938mg,9.56mmol)加入瓶中,加入10mL二氧六环,室温搅拌均匀,加入Pd(dppf)Cl2(233mg,0.318676mmol),氩气保护下加热至100℃反应6h。将反应冷却至室温,加水,减压抽滤,收集滤液,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=5:1,得白色固体517mg,收率45.67%,熔点110-111℃。
1H NMR(500MHz,DMSO-d6)δ9.09–8.99(m,1H),7.90(q,J=6.7,6.1Hz,2H),7.60–7.44(m,4H),7.43–7.28(m,2H),4.55(q,J=7.0,6.4Hz,2H),1.30(dd,J=9.7,4.7Hz,12H).
MS(ESI)m/z 356.08(M+H)+.
(3)叔丁基4-(4-(4-(苯甲酰胺甲基)-3-氟苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡
咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐的制备
将4-(4-氯)叔丁基-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(400mg,0.86mmol),N-(2-氟-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苄基)苯甲酰胺(458mg,1.29mmol)和碳酸钾(237mg,1.72mmol)加入瓶中,加入4mL二氧六环和2mL水,室温搅拌均匀,加入Pd(dppf)Cl2(63mg,0.086mmol),氩气保护下加热至100℃反应10h。将反应冷却至室温,加水,减压抽滤,收集滤液,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=5:1,得黄色固体320mg,收率56.56%,熔点81-82℃。
1H NMR(500MHz,DMSO-d6)δ9.04(s,1H),8.88(s,1H),7.87(d,J=7.7Hz,2H),7.74(s,1H),7.54–7.36(m,7H),5.62(s,2H),5.29(d,J=16.7Hz,1H),4.57(d,J=5.8Hz,2H),3.69(s,2H),3.56(q,J=9.5,7.8Hz,2H),3.42(q,J=6.6Hz,2H),1.91(s,2H),1.37(s,9H),0.82(t,J=7.9Hz,2H),-0.11(s,9H).
MS(ESI)m/z 658.33(M+H)+.
(4)N-(4-(5-(1-(丁-2-炔酰基)-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-)吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)苯甲酰胺的制备
将叔丁基4-(4-(4-(苯甲酰胺甲基)-3-氟苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(160mg,0.243mmol)加入瓶中,加入1.5mL无水乙醇,室温搅拌均匀,滴加浓盐酸(2mL,24mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无
水硫酸钠干燥,浓缩得油状物。将油状物溶于2mL二氯甲烷,在冰盐浴的条件下加入DIEA(130μL,0.729mmol)和NaOH(12mg,0.3mmol),滴加2-丁炔酰氯(38μL,0.44mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得黄色固体76mg,收率50.14%,熔点82-83℃。
1H NMR(500MHz,DMSO-d6)δ9.05(d,J=13.7Hz,1H),8.91(s,1H),7.90(t,J=7.1Hz,2H),7.78(d,J=11.7Hz,1H),7.47(tt,J=30.9,8.4Hz,6H),5.66(s,2H),5.35(d,J=9.9Hz,1H),4.60(d,J=5.8Hz,2H),4.05(s,1H),3.84(s,1H),3.58(t,J=7.9Hz,2H),3.53(s,1H),3.41–3.36(m,1H),1.99(s,3H),1.95(s,1H),1.24(s,1H),0.85(t,J=7.8Hz,2H),-0.08(s,9H).
MS(ESI)m/z 624.33(M+H)+.
(5)标题化合物的制备
将N-(4-(5-(1-(丁-2-炔酰基)-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-)吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)苯甲酰胺(76mg,0.122mmol)溶于2mL二氯甲烷,在冰浴条件下滴加三氟乙酸(815μL,10.98mmol),室温搅拌7h。在冰浴条件下加入NaOH水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得白色固体36mg,收率59.85%,熔点146-147℃。1H NMR(500MHz,DMSO-d6)δ12.33(s,1H),9.04(dd,J=12.7,6.3Hz,1H),8.83(s,1H),7.90(t,J=6.8Hz,2H),7.62–7.52(m,2H),7.50–7.37(m,5H),5.30(d,J=10.9Hz,1H),4.60(d,J=5.9Hz,2H),4.05(s,1H),3.83(s,1H),3.53(t,J=5.7Hz,1H),3.38(t,J=5.3Hz,1H),2.04(s,1H),1.99(s,4H).
HRMS calcd.For C29H25O2N5F(M+H)+494.1987,found 494.2026.
实施例8
N-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)苯甲酰胺
(1)N-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-)d]嘧啶-4-基)-2-氟苄基)苯甲酰胺的制备
将叔丁基4-(4-(4-(苯甲酰胺甲基)-3-氟苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(160mg,0.243mmol)加入瓶中,加入1.5mL无水乙醇,室温搅拌均匀,滴加浓盐酸(2mL,24mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥,浓缩得油状物。将油状物溶于2mL二氯甲烷,在冰盐浴的条件下加入DIEA(130μL,0.729mmol)和NaOH(12mg,0.3mmol),滴加丙烯酰氯(45μL,0.55mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得白色固体50mg,收率33.78%,熔点63-64℃。
1H NMR(500MHz,DMSO-d6)δ9.12–9.03(m,1H),8.91(s,1H),7.90(d,J=7.5Hz,2H),7.78(d,J=21.6Hz,1H),7.57–7.38(m,6H),6.69(dd,J=16.6,10.4Hz,1H),6.11(t,J=15.3Hz,1H),5.65(d,J=11.6Hz,3H),5.43–5.20(m,1H),4.58(d,J=5.8Hz,2H),3.91(d,J=12.3Hz,2H),3.58(t,J=8.0Hz,2H),3.42(d,J=31.6Hz,2H),2.03–1.96(m,2H),0.85(t,J=7.9Hz,2H),-0.08(s,9H).
MS(ESI)m/z 612.30(M+H)+.
(2)标题化合物的制备
将N-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-)d]嘧啶-4-基)-2-氟苄基)苯甲酰胺(37mg,0.06mmol)溶于1mL二氯甲烷,在冰浴条件下滴加三氟乙酸(400μL,5.4mmol),室温搅拌7h。在冰浴条件下加入NaOH水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得白色固体17mg,收率58.90%,熔点159-160℃。
1H NMR(500MHz,DMSO-d6)δ12.33(d,J=15.6Hz,1H),9.10–9.03(m,1H),8.83(s,1H),7.90(d,J=6.5Hz,2H),7.63–7.50(m,2H),7.50–7.36(m,5H),6.69(dd,J=17.0,9.8Hz,1H),6.15–6.06(m,1H),5.69–5.61(m,1H),5.28(d,J=99.1Hz,1H),4.58(d,J=5.7Hz,2H),3.90(s,2H),3.46(s,1H),3.38(s,1H),2.04(d,J=6.5Hz,1H),1.98(d,J=10.4Hz,1H).HRMS calcd.For C28H25O2N5F(M+H)+482.1987,found 482.2021.
实施例9
N-(4-(5-(1-(丁-2-炔酰基)-1,2,3,6-四氢吡啶-4-基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)-4-环丙基苯甲酰胺
(1)N-(4-溴-2-氟苄基)-4-环丙基苯甲酰胺的制备
将2-氟-4-溴苄胺(214mg,1mmol)加入瓶中,用2mL二氯甲烷溶解,加入二异丙基乙胺(194μL,1.1mmol),搅拌均匀,冰浴条件下,滴加4-环丙基苯甲酰氯(195mg,1.05mmol),室温搅拌1.5h。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=10:1,得白色固体319mg,收率91.63%。
熔点91-92℃
1H NMR(500MHz,DMSO-d6)δ8.91(s,1H),7.77(d,J=8.0Hz,2H),7.51(d,J=9.8Hz,1H),7.39(d,J=8.4Hz,1H),7.30(t,J=8.2Hz,1H),7.16(d,J=8.1Hz,2H),4.44(d,J=5.7Hz,2H),2.01–1.94(m,1H),1.00(d,J=8.2Hz,2H),0.73(d,J=5.2Hz,2H).
MS(ESI)m/z 348.04(M+H)+.
(2)4-环丙基-N-(2-氟-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苄基)苯甲酰胺的制备
将N-(4-溴-2-氟苄基)-4-环丙基苯甲酰胺(360mg,1.034mmol),联硼酸频那醇酯(394mg,1.551mmol)和醋酸钾(304mg,3.102mmol)加入瓶中,加入5.5mL二氧六环,室温搅拌均匀,加入Pd(dppf)Cl2(76mg,0.1034mmol),氩气保护下加热至100℃反应6h。将反应冷却至室温,加水,减压抽滤,收集滤液,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=5:1,得白色固体320mg,
收率78.30%,熔点95-96℃。
1H NMR(500MHz,DMSO-d6)δ8.92(t,J=4.6Hz,1H),7.78(d,J=8.0Hz,2H),7.45(d,J=7.5Hz,1H),7.39–7.29(m,2H),7.16(d,J=8.0Hz,2H),4.51(d,J=5.8Hz,2H),2.01–1.95(m,1H),1.29(s,12H),1.03–0.98(m,2H),0.76–0.71(m,2H).
MS(ESI)m/z 396.17(M+H)+.
(3)叔丁基4-(4-(4-((4-环丙基苯甲酰胺基)甲基)-3-氟苯基)-7-((2-(三甲基甲硅烷基)乙氧基)
甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐的制备
将4-(4-氯)叔丁基-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(300mg,0.6423mmol),4-环丙基-N-(2-氟-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苄基)苯甲酰胺(330mg,0.835mmol)和碳酸钾(177mg,1.2846mmol)加入瓶中,加入3mL二氧六环和1.5mL水,室温搅拌均匀,加入Pd(dppf)Cl2(47mg,0.06423mmol),氩气保护下加热至100℃反应10h。将反应冷却至室温,加水,减压抽滤,收集滤液,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=2:1,得白色固体275mg,收率61.32%,熔点65-66℃。
1H NMR(500MHz,DMSO-d6)δ8.96(t,J=5.8Hz,1H),8.91(s,1H),7.81–7.74(m,3H),7.51–7.45(m,2H),7.40(d,J=10.8Hz,1H),7.15(d,J=8.0Hz,2H),5.65(s,2H),5.33(s,1H),4.57(d,J=5.7Hz,2H),3.72(s,2H),3.58(t,J=7.9Hz,2H),3.20(s,2H),1.96(d,J=13.6Hz,2H),1.40(s,9H),1.24(s,1H),1.00(d,J=8.1Hz,2H),0.85(t,J=7.9Hz,2H),0.73(d,J=5.5Hz,2H),-0.08(s,9H).
MS(ESI)m/z 698.30(M+H)+.
(4)N-(4-(5-(1-(丁-2-炔酰基)-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-)吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)-4-环丙基苯甲酰胺的制备
将叔丁基4-(4-(4-((4-环丙基苯甲酰胺基)甲基)-3-氟苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(211mg,0.303mmol)加入瓶中,加入2.5mL无水乙醇,室温搅拌均匀,滴加浓盐酸(1.2mL,15.15mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥,浓缩得油状物。将油状物溶于3mL二氯甲烷,在冰盐浴的条件下加入DIEA(160μL,0.909mmol)和NaOH(17mg,0.42mmol),滴加2-丁炔酰氯(50μL,0.5454mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得黄色固体150mg,收率74.63%,熔点67-68℃。
1H NMR(400MHz,DMSO-d6)δ8.96(dt,J=11.5,6.0Hz,1H),8.91(s,1H),7.79(dd,J=8.6,5.3Hz,3H),7.52–7.36(m,3H),7.15(d,J=8.3Hz,2H),5.65(s,2H),5.35(s,1H),4.58(d,J=5.7Hz,2H),4.04(s,1H),3.83(s,1H),3.57(t,J=8.0Hz,2H),3.51(t,J=5.6Hz,1H),3.36(d,J=6.6Hz,1H),2.04(s,1H),2.01–1.90(m,5H),1.04–0.96(m,2H),0.85(t,J=8.0Hz,2H),0.77–0.70(m,2H),-0.08(s,8H).
MS(ESI)m/z 664.33(M+H)+.
(5)标题化合物的制备
将N-(4-(5-(1-(丁-2-炔酰基)-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-)吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)-4-环丙基苯甲酰胺(150mg,0.226mmol)溶于3mL二氯甲烷,在冰浴条件下滴加三氟乙酸(1.5mL,20.34mmol),室温搅拌7h。在冰浴条件下加入NaOH水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得白色固体96mg,收率79.61%,熔点135-136℃。1H NMR(400MHz,DMSO-d6)δ12.29(s,1H),8.96–8.87(m,1H),8.78(s,1H),7.74(dd,J=8.4,4.5Hz,2H),7.55(dd,J=10.2,2.4Hz,1H),7.45–7.29(m,3H),7.10(d,J=8.4Hz,2H),5.24(d,J=8.8Hz,1H),4.52(d,J=5.4Hz,2H),3.99(s,1H),3.80–3.71(m,1H),3.46(t,J=5.8Hz,1H),3.32(t,J=5.9Hz,1H),1.99(s,1H),1.96–1.88(m,5H),0.96(dd,J=8.4,2.3Hz,2H),0.69(dd,J=4.9,2.1Hz,2H).
HRMS calcd.For C32H29O2N5F(M+H)+534.2300,found 534.2295.
实施例10
N-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)-4-环丙基苯甲酰胺
(1)N-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-)d]嘧啶-4-基)-2-氟苄基)-4-环丙基苯甲酰胺的制备
将叔丁基4-(4-(4-((4-环丙基苯甲酰胺基)甲基)-3-氟苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(211mg,0.303mmol)加入瓶中,加入2.5mL无水乙醇,室温搅拌均匀,滴加浓盐酸(1.2mL,15.15mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥,浓缩得油状物。将油状物溶于3mL二氯甲烷,在冰盐浴的条件下加入DIEA(160μL,0.909mmol)和NaOH(17mg,0.42mmol),滴加丙烯酰氯(55μL,0.682mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得白色固体124mg,收率62.78%,熔点66-67℃。
1H NMR(400MHz,DMSO-d6)δ9.01–8.94(m,1H),8.91(s,1H),7.83–7.74(m,3H),7.50–7.36(m,3H),7.14(d,J=7.9Hz,2H),6.68(dd,J=16.6,10.5Hz,1H),6.11(dd,J=17.0,9.9Hz,1H),5.65(d,J=8.0Hz,3H),5.32(d,J=77.7Hz,1H),4.56(d,J=5.7Hz,2H),3.90(s,2H),3.57(t,J=8.0Hz,2H),3.48–3.41(m,1H),3.40–3.34(m,1H),2.01(s,1H),1.97(dt,J=8.4,3.7Hz,2H),1.03–0.97(m,2H),0.89–0.81(m,3H),0.76–0.69(m,2H),-0.09(s,9H).
MS(ESI)m/z 652.35(M+H)+.
(2)标题化合物的制备
将N-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-)d]嘧啶-4-基)-2-氟苄基)-4-环丙基苯甲酰胺(110mg,0.169mmol)溶于1mL二氯甲烷,在冰浴条件下滴加三氟乙酸(1.13mL,15.21mmol),室温搅拌7h。在冰浴条件下加入NaOH水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得白色固体76mg,收率86.31%,熔点135-136℃。1H NMR(400MHz,DMSO-d6)δ12.34(d,J=13.3Hz,1H),9.01–8.93(m,1H),8.82(s,1H),7.78(d,J=7.3Hz,2H),7.60(d,J=18.4Hz,1H),7.41(d,J=16.9Hz,3H),7.14(dd,J=7.3,3.2Hz,2H),6.68(dd,J=16.5,10.6Hz,1H),6.10(dd,J=17.1,9.0Hz,1H),5.66(t,J=8.1Hz,1H),5.27(d,J=84.0Hz,1H),4.56(d,J=5.7Hz,2H),3.89(s,2H),3.41(dt,J=33.0,4.1Hz,2H),2.03(s,1H),1.95(dd,J=8.0,5.1Hz,2H),1.00(dd,J=8.4,2.2Hz,3H),0.73(dd,J=4.7,1.9Hz,2H).
HRMS calcd.For C31H29O2N5F(M+H)+522.2300,found 522.2291.
实施例11
N-(4-(5-(1-(丁-2-炔酰基)哌啶-4-基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)-4-(叔丁基)苯甲酰胺
(1)叔丁基4-(4-(4-((4-(叔丁基)苯甲酰氨基)甲基)-3-氟苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)哌啶-1-羧酸盐的制备
将叔丁基4-(4-(4-((4-(叔丁基)苯甲酰氨基)甲基)-3-氟苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(410mg,0.574mmol)加入瓶中,溶于16mL甲醇和8mL乙酸乙酯,加入钯碳(230mg,10%),通入氢气,室温下搅拌48h。硅藻土过滤除去Pd/C,浓缩反应液,得白色固体400mg,收率97.32%,熔点87-88℃。
1H NMR(500MHz,DMSO-d6)δ9.04(t,J=6.1Hz,1H),8.85(s,1H),7.83(d,J=8.2Hz,2H),7.59(s,1H),7.53(t,J=7.7Hz,1H),7.50–7.39(m,4H),5.61(s,2H),4.60(d,J=5.8Hz,2H),3.84(s,2H),3.54(t,J=7.9Hz,2H),2.61(t,J=12.1Hz,1H),2.36(s,2H),1.52–1.43(m,2H),1.36(s,9H),1.30(s,9H),1.25–1.18(m,2H),0.82(t,J=7.9Hz,2H),-0.09(s,9H).
MS(ESI)m/z 716.40(M+H)+.
(2)N-(4-(5-(1-(丁-2-炔酰基)哌啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶)-4-基)-2-氟苄基)-4-(叔丁基)苯甲酰胺的制备
将叔丁基4-(4-(4-((4-(叔丁基)苯甲酰氨基)甲基)-3-氟苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)哌啶-1-羧酸盐(217mg,0.303mmol)加入瓶中,加入2.5mL无水乙醇,室温搅拌均匀,滴加浓盐酸(1.2mL,15.15mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥,浓缩得油状物。将油状物溶于3mL二氯甲烷,在冰盐浴的条件下加入DIEA(160μL,0.909mmol)和NaOH(17mg,0.42mmol),滴加2-丁炔酰氯(50μL,0.5454mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得白色固体131mg,收率63.22%。
熔点82-83℃
1H NMR(400MHz,DMSO-d6)δ9.02(t,J=5.8Hz,1H),8.81(s,1H),7.79–7.74(m,2H),7.55(s,1H),7.50(t,J=7.7Hz,1H),7.44–7.35(m,4H),5.56(s,2H),4.55(d,J=5.8Hz,2H),4.17(d,J=13.1Hz,1H),4.05(d,J=13.1Hz,1H),3.52–3.46(m,2H),2.59(d,J=12.8Hz,2H),2.20(t,J=12.2Hz,1H),1.92(s,3H),1.50(d,J=13.0Hz,2H),1.25(s,9H),1.21–1.19(m,2H),0.81–0.75(m,2H),-0.14(s,9H).
MS(ESI)m/z 682.36(M+H)+.
(3)标题化合物的制备
将N-(4-(5-(1-(丁-2-炔酰基)哌啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶)-4-基)-2-氟苄基)-4-(叔丁基)苯甲酰胺(55mg,0.08mmol)溶于1mL二氯甲烷,在冰浴条件下滴加三氟乙酸(420μL,5.646mmol),室温搅拌7h。在冰浴条件下加入NaOH
水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得白色固体35mg,收率79.30%,熔点156-157℃。
1H NMR(400MHz,DMSO-d6)δ12.12(s,1H),9.08(t,J=5.9Hz,1H),8.77(s,1H),7.82(d,J=8.5Hz,2H),7.57–7.50(m,1H),7.49–7.45(m,2H),7.43–7.38(m,2H),4.60(d,J=5.7Hz,2H),4.23(d,J=13.4Hz,1H),4.11(d,J=15.8Hz,1H),2.71–2.57(m,2H),2.24(s,1H),1.98(s,3H),1.54(d,J=12.4Hz,2H),1.30(s,9H),1.24(s,2H).
HRMS calcd.For C33H35O2N5F(M+H)+552.2769,found 552.2813.
实施例12
N-(4-(5-(1-丙烯酰哌啶-4-基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)-4-(叔丁基)苯甲酰胺
(1)N-(4-(5-(1-丙烯酰哌啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)-4-(叔丁基)苯甲酰胺的制备
将叔丁基4-(4-(4-((4-(叔丁基)苯甲酰氨基)甲基)-3-氟苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)哌啶-1-羧酸盐(217mg,0.303mmol)加入瓶中,加入2.5mL无水乙醇,室温搅拌均匀,滴加浓盐酸(1.2mL,15.15mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥,浓缩得油状物。将油状物溶于3mL二氯甲烷,在冰盐浴的条件下加入DIEA(160μL,0.909mmol)和NaOH(17mg,0.42mmol),滴加丙烯酰氯(55μL,0.682mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得白色固体118mg,收率58.36%。
熔点79-80℃
1H NMR(500MHz,DMSO-d6)δ9.05(t,J=5.8Hz,1H),8.85(s,1H),7.82(d,J=8.1Hz,2H),7.60–7.52(m,2H),7.44(dd,J=15.9,8.3Hz,4H),6.66(dd,J=16.7,10.4Hz,1H),6.03(d,J=16.8Hz,1H),5.60(d,J=11.0Hz,3H),4.60(d,J=5.8Hz,2H),4.37(d,J=12.8Hz,1H),3.87(d,J=13.5Hz,1H),3.54(t,J=8.0Hz,2H),2.64(dt,J=39.0,13.5Hz,2H),2.25(t,J=13.5Hz,1H),1.53(dd,J=63.0,7.5Hz,2H),1.29(s,9H),1.24(s,2H),0.86–0.79(m,2H),-0.09(s,9H).
MS(ESI)m/z 670.33(M+H)+.
(2)标题化合物的制备
将N-(4-(5-(1-丙烯酰哌啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)-4-(叔丁基)苯甲酰胺(40mg,0.06mmol)溶于1mL二氯甲烷,在冰浴条件下滴加三氟乙酸(400μL,5.4mmol),室温搅拌7h。在冰浴条件下加入NaOH水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得白色固体23mg,收率71.04%,熔点154-155℃。
1H NMR(500MHz,DMSO-d6)δ12.05(s,1H),9.02(t,J=5.7Hz,1H),8.73(s,1H),7.79(d,J=8.1Hz,2H),7.51(t,J=7.7Hz,1H),7.45–7.33(m,6H),6.62(dd,J=16.9,10.4Hz,1H),6.00(d,J=15.0Hz,1H),5.56(d,J=12.0Hz,1H),4.57(d,J=5.8Hz,2H),4.34(d,J=13.0Hz,1H),3.83(d,J=10.6Hz,1H),2.63–2.53(m,2H),2.21(s,1H),1.55(d,J=12.6Hz,1H),1.43(d,J=11.9Hz,1H),1.26(s,9H),1.21(s,2H).
HRMS calcd.For C32H35O2N5F(M+H)+540.2769,found 540.2809.
实施例13
N-(4-(5-(1-(丁-2-炔酰基)哌啶-4-基)-7H-吡咯并[2,3-d]嘧啶-4-基)苄基)-4-(叔丁基))苯甲酰胺
(1)叔丁基4-(4-(4-((4-(叔丁基)苯甲酰胺基)甲基)苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)哌啶-1-羧酸盐的制备
将叔丁基4-(4-(4-((4-(叔丁基)苯甲酰胺基)甲基)苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(290mg,0.4167mmol)加入瓶中,溶于20mL甲醇和10mL乙酸乙酯,加入钯碳(250mg,10%),通入氢气,室温下搅拌48h。硅藻土过滤除去Pd/C,浓缩反应液,得白色固体270mg,收率92.78%,熔点92-93℃。1H NMR(500MHz,DMSO-d6)δ9.05(t,J=6.1Hz,1H),8.83(s,1H),7.83(d,J=8.2Hz,2H),7.60–7.53(m,3H),7.49(t,J=7.5Hz,4H),5.61(s,2H),4.57(d,J=6.0Hz,2H),3.80(s,2H),3.54(t,J=7.9Hz,2H),2.64(t,J=11.5Hz,1H),2.32(s,2H),1.44(d,J=12.6Hz,2H),1.35(s,9H),1.30(s,9H),1.17(d,J=11.9Hz,2H),0.82(t,J=7.9Hz,2H),-0.10(s,9H).
MS(ESI)m/z 698.38(M+H)+.
(2)N-(4-(5-(1-(丁-2-炔酰基)哌啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶)-4-基)苄基)-4-(叔丁基)苯甲酰胺的制备
将叔丁基4-(4-(4-((4-(叔丁基)苯甲酰胺基)甲基)苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)哌啶-1-羧酸盐(135mg,0.1934mmol)加入瓶中,加入2mL无水乙醇,室温搅拌均匀,滴加浓盐酸(483μL,5.8mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥,浓缩得油状物。将油状物溶于1.5mL二氯甲烷,在冰盐浴的条件下加入DIEA(100μL,0.58mmol)和NaOH(12mg,0.3mmol),滴加2-丁炔酰氯(30μL,0.348mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得白色固体85mg,收率66.41%,熔点96-98℃。
1H NMR(500MHz,DMSO-d6)δ9.05(t,J=6.1Hz,1H),8.84(s,1H),7.82(d,J=8.2Hz,2H),7.60–7.53(m,3H),7.51(d,J=7.8Hz,2H),7.47(d,J=8.2Hz,2H),5.60(s,2H),4.57(d,J=6.0Hz,2H),4.20(t,J=12.3Hz,1H),4.05(dd,J=20.4,10.3Hz,1H),3.54(t,J=7.9Hz,2H),2.66(dt,J=25.6,12.3Hz,2H),2.22(t,J=12.7Hz,1H),1.97(s,3H),1.52(d,J=12.8Hz,2H),1.30(s,9H),1.24(s,2H),0.85–0.80(m,2H),-0.09(s,9H).
MS(ESI)m/z 664.37(M+H)+.
(3)标题化合物的制备
将N-(4-(5-(1-(丁-2-炔酰基)哌啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶)-4-基)苄基)-4-(叔丁基)苯甲酰胺(75mg,0.113mmol)溶于1.5mL二氯甲烷,在冰浴条件下滴加三氟乙酸(760μL,10.2mmol),室温搅拌7h。在冰浴条件下加入NaOH水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得白色固体43mg,收率71.30%,熔点156-157℃。
1H NMR(400MHz,DMSO-d6)δ12.06(s,1H),9.07(t,J=6.1Hz,1H),8.76(s,1H),7.82(d,J=8.4Hz,2H),7.57(d,J=7.9Hz,2H),7.49(dd,J=10.8,8.4Hz,4H),7.37(s,1H),4.57(d,J=6.0Hz,2H),4.20(d,J=13.5Hz,1H),4.08(d,J=12.5Hz,1H),2.67–2.60(m,2H),2.26–2.16(m,1H),1.97(s,3H),1.51(d,J=12.0Hz,2H),1.31(s,9H),1.25(s,2H).
HRMS calcd.For C33H36O2N5(M+H)+534.2864,found 534.2904.
实施例14
N-(4-(5-(1-丙烯酰基哌啶-4-基)-7H-吡咯并[2,3-d]嘧啶-4-基)苄基)-4-(叔丁基)苯甲酰胺
(1)N-(4-(5-(1-丙烯酰哌啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)苄基)-4-(叔丁基)苯甲酰胺的制备
将叔丁基4-(4-(4-((4-(叔丁基)苯甲酰胺基)甲基)苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)哌啶-1-羧酸盐(135mg,0.1934mmol)加入瓶中,加入2mL无水乙醇,室温搅拌均匀,滴加浓盐酸(483μL,5.8mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥,浓缩得油状物。将油状物溶于1.5mL二氯甲烷,在冰盐浴的条件下加入DIEA(200μL,1.16mmol)和NaOH(12mg,0.3mmol),滴加丙烯酰氯(35μL,0.435mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,
柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得白色固体64mg,收率50.79%,熔点82-83℃。
1H NMR(400MHz,DMSO-d6)δ9.02(t,J=6.1Hz,1H),8.79(s,1H),7.79–7.73(m,2H),7.53(d,J=8.1Hz,2H),7.50–7.44(m,3H),7.43–7.37(m,2H),6.60(dd,J=16.7,10.5Hz,1H),5.97(dd,J=16.7,2.4Hz,1H),5.56(s,2H),5.53(d,J=2.5Hz,1H),4.52(d,J=6.0Hz,2H),4.28(d,J=12.7Hz,1H),3.78(d,J=13.3Hz,1H),3.54–3.43(m,2H),2.66(t,J=12.0Hz,1H),2.53(t,J=12.9Hz,1H),2.18(t,J=12.5Hz,1H),1.51(d,J=13.0Hz,1H),1.38(d,J=11.8Hz,1H),1.24(s,9H),1.10(d,J=13.3Hz,2H),0.80–0.73(m,2H),-0.15(s,9H).
MS(ESI)m/z 652.37(M+H)+.
(2)标题化合物的制备
将N-(4-(5-(1-丙烯酰哌啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)苄基)-4-(叔丁基)苯甲酰胺(64mg,0.1mmol)溶于1.5mL二氯甲烷,在冰浴条件下滴加三氟乙酸(670μL,9mmol),室温搅拌7h。在冰浴条件下加入NaOH水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得白色固体37mg,收率70.92%。
熔点152-153℃
1H NMR(400MHz,DMSO-d6)δ11.98(s,1H),9.02(t,J=6.0Hz,1H),8.70(s,1H),7.77(d,J=8.5Hz,2H),7.52(d,J=8.1Hz,2H),7.43(dd,J=15.2,8.3Hz,4H),7.30(d,J=2.1Hz,1H),6.59(dd,J=16.7,10.5Hz,1H),5.97(dd,J=16.7,2.4Hz,1H),5.54(dd,J=10.5,2.4Hz,1H),4.52(d,J=5.9Hz,2H),4.29(d,J=12.6Hz,1H),3.78(d,J=14.6Hz,1H),2.68–2.51(m,2H),2.21–2.12(m,1H),1.51(d,J=13.9Hz,1H),1.38(d,J=13.2Hz,1H),1.24(s,9H),1.20(s,2H).
HRMS calcd.For C32H36O2N5(M+H)+522.2864,found 522.2903.
实施例15
N-(4-(5-(1-(丁-2-炔酰基)哌啶-4-基))-7H-吡咯并[2,3-d]嘧啶-4-基)-2-甲基苄基)-4-(叔丁基)苯甲酰胺
(1)叔丁基4-(4-(4-((4-(叔丁基)苯甲酰胺基)甲基)-3-甲基苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)哌啶-1-羧酸盐的制备
将叔丁基4-(4-(4-((4-(叔丁基)苯甲酰胺基)甲基)-3-甲基苯基)-7-((2-(三甲基甲硅烷基))乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(450mg,0.6338mmol)加入瓶中,溶于20mL甲醇和10mL乙酸乙酯,加入钯碳(500mg,10%),通入氢气,室温下搅拌48h。硅藻土过滤除去Pd/C,浓缩反应液,得白色固体420mg,收率93.66%,熔点92-93℃。
1H NMR(400MHz,DMSO-d6)δ8.94(t,J=5.9Hz,1H),8.82(s,1H),7.89–7.81(m,2H),7.56(d,J=0.8Hz,1H),7.51–7.46(m,2H),7.42(dd,J=9.0,1.2Hz,3H),5.61(s,2H),4.55(d,J=5.9Hz,2H),3.83(s,2H),3.53(dd,J=8.4,7.5Hz,2H),2.65(t,J=11.6Hz,1H),2.45(s,3H),2.40–2.20(m,2H),1.52–1.43(m,2H),1.35(s,9H),1.30(s,9H),1.24–1.16(m,2H),0.86–0.78(m,2H),-0.10(s,9H).
MS(ESI)m/z 712.39(M+H)+.
(2)N-(4-(5-(1-(丁-2-炔酰基)哌啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶)-4-基)-2-甲基苄基)-4-(叔丁基)苯甲酰胺的制备
将叔丁基4-(4-(4-((4-(叔丁基)苯甲酰胺基)甲基)-3-甲基苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)哌啶-1-羧酸盐(216mg,0.303mmol)加入瓶中,加入2.5mL无水乙醇,室温搅拌均匀,滴加浓盐酸(1.2mL,15.15mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥,浓缩得油状物。将油状物溶于3mL二氯甲烷,在冰盐浴的条件下加入DIEA(160μL,0.909mmol)和NaOH(17mg,0.42mmol),滴加2-丁炔酰氯(50μL,0.5454mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得白色固体125mg,收
率60.85%。
熔点74-75℃
1H NMR(500MHz,DMSO-d6)δ8.98–8.87(m,1H),8.83(s,1H),7.83(d,J=8.1Hz,2H),7.56(s,1H),7.47(d,J=8.1Hz,2H),7.42(d,J=6.3Hz,3H),5.60(s,2H),4.55(d,J=5.8Hz,2H),4.22(d,J=13.1Hz,1H),4.11(d,J=13.6Hz,1H),3.54(t,J=7.9Hz,2H),2.67(q,J=14.0,12.8Hz,2H),2.46(s,3H),2.23(t,J=12.2Hz,1H),1.97(s,3H),1.54(s,2H),1.30(s,9H),1.23–1.13(m,2H),0.82(t,J=7.9Hz,2H),-0.09(s,9H).
MS(ESI)m/z 678.38(M+H)+.
(3)标题化合物的制备
将N-(4-(5-(1-(丁-2-炔酰基)哌啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶)-4-基)-2-甲基苄基)-4-(叔丁基)苯甲酰胺(68mg,0.1mmol)溶于1.5mL二氯甲烷,在冰浴条件下滴加三氟乙酸(670μL,9mmol),室温搅拌7h。在冰浴条件下加入NaOH水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得白色固体35mg,收率63.90%,熔点162-163℃。
1H NMR(500MHz,DMSO-d6)δ12.01(s,1H),8.94–8.89(m,1H),8.74(s,1H),7.83(d,J=7.9Hz,2H),7.47(d,J=7.7Hz,2H),7.41(d,J=4.4Hz,3H),7.36(s,1H),4.55(d,J=4.3Hz,2H),4.22(d,J=12.9Hz,1H),4.11(d,J=17.0Hz,1H),2.65(t,J=11.9Hz,2H),2.46(s,3H),2.21(t,J=12.5Hz,1H),1.97(s,3H),1.60–1.49(m,2H),1.30(s,9H),1.24(s,2H).
HRMS calcd.For C34H38O2N5(M+H)+548.3020,found 548.3013.
实施例16
N-(4-(5-(1-丙烯酰基哌啶-4-基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-甲基苄基)-4-(叔丁基)苯甲酰胺
(1)N-(4-(5-(1-丙烯酰哌啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-甲基苄基)-4-(叔丁基)苯甲酰胺的制备
将叔丁基4-(4-(4-((4-(叔丁基)苯甲酰胺基)甲基)-3-甲基苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)哌啶-1-羧酸盐(216mg,0.303mmol)加入瓶中,加入2.5mL无水乙醇,室温搅拌均匀,滴加浓盐酸(1.2mL,15.15mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥,浓缩得油状物。将油状物溶于3mL二氯甲烷,在冰盐浴的条件下加入DIEA(160μL,0.909mmol)和NaOH(17mg,0.42mmol),滴加丙烯酰氯(55μL,0.682mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得白色固体103mg,收率51.04%,
熔点73-74℃。
1H NMR(400MHz,DMSO-d6)δ8.89(t,J=5.8Hz,1H),8.78(s,1H),7.81–7.74(m,2H),7.50(d,J=1.0Hz,1H),7.44–7.34(m,5H),6.61(dd,J=16.7,10.4Hz,1H),5.98(dd,J=16.7,2.5Hz,1H),5.58–5.49(m,3H),4.50(d,J=5.8Hz,2H),4.32(d,J=12.8Hz,1H),3.82(d,J=13.6Hz,1H),3.54–3.42(m,2H),2.61(dt,J=53.7,12.2Hz,2H),2.41(s,3H),2.23–2.12(m,1H),1.47(dd,J=45.5,13.2Hz,2H),1.24(s,9H),1.22–1.17(m,2H),0.83–0.70(m,2H),-0.15(s,9H).
MS(ESI)m/z 666.37(M+H)+.
(2)标题化合物的制备
将N-(4-(5-(1-丙烯酰哌啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-甲基苄基)-4-(叔丁基)苯甲酰胺(67mg,0.1mmol)溶于1.5mL二氯甲烷,在冰浴条件下滴加三氟乙酸(670μL,9mmol),室温搅拌7h。在冰浴条件下加入NaOH水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得白色固体27mg,收率50.40%,熔点164-165℃。
1H NMR(500MHz,DMSO-d6)δ12.01(s,1H),8.93(s,1H),8.74(s,1H),7.83(d,J=6.6Hz,2H),7.53–7.37(m,6H),7.34(s,1H),6.70–6.59(m,1H),6.02(d,J=17.0Hz,1H),5.59(d,J=9.0Hz,1H),4.55(s,2H),4.37(d,J=11.4Hz,1H),3.86(d,J=11.2Hz,1H),2.73–2.64(m,
1H),2.64–2.54(m,1H),2.46(s,3H),2.22(s,1H),1.57(d,J=11.9Hz,1H),1.46(d,J=7.9Hz,1H),1.29(s,9H),1.24(s,2H).
HRMS calcd.For C33H38O2N5(M+H)+536.3020,found 536.3013.
实施例17
1-(4-(5-(1-(丁-2-炔酰基)-1,2,3,6-四氢吡啶)-4-基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)-3-苯基脲
(1)(4-溴-2-氟苄基)氨基甲酸苯酯的制备
将4-溴-2-氟苄胺(700mg,3.362mmol)溶于4.5mL DMF,在冰盐浴条件下滴加吡啶(540μL,6.724mmol),滴加氯甲酸苯酯(645μL,5.043mmol),室温下搅拌10h。加水,析出白色固体,减压抽滤,收集滤饼,得白色固体1g,收率91.83%,熔点77-78℃。
1H NMR(500MHz,DMSO-d6)δ8.31(t,J=5.8Hz,1H),7.54(d,J=9.8Hz,1H),7.51–7.42(m,2H),7.37(t,J=7.5Hz,3H),7.20(t,J=7.6Hz,1H),7.11(d,J=7.9Hz,1H),4.28(d,J=6.0Hz,2H).
MS(ESI)m/z 324.00(M+H)+.
(2)1-(4-溴-2-氟苄基)-3-苯基脲的制备
将(4-溴-2-氟苄基)氨基甲酸苯酯(1.383g,4.267mmol)溶于DMF,加入二异丙基乙胺(3mL,17.068mmol),滴加苯胺(780μL,8.534mmol),室温下搅拌5h。加水,析出白色固体,减压抽滤,收集滤饼,得白色固体1.14g,收率82.67%。
熔点98-99℃
1H NMR(500MHz,DMSO-d6)δ8.59(s,1H),7.54–7.46(m,1H),7.45–7.30(m,4H),7.21(t,J=7.8Hz,2H),6.89(t,J=7.4Hz,1H),6.63(t,J=6.1Hz,1H),4.30(d,J=5.9Hz,2H).
MS(ESI)m/z 323.02(M+H)+.
(3)1-(2-氟-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苄基)-3-苯基脲的制备
将1-(4-溴-2-氟苄基)-3-苯基脲(500mg,1.548mmol),联硼酸频那醇酯(590mg,2.322mmol)和醋酸钾(456mg,4.644mmol)加入瓶中,加入8mL二氧六环,室温搅拌均匀,加入Pd(dppf)Cl2(113mg,0.1548mmol),氩气保护下加热至100℃反应6h。将反应冷却至室温,加水,减压抽滤,收集滤液,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=5:1,得白色固体468mg,收率81.68%,熔点117-118℃。
1H NMR(400MHz,DMSO-d6)δ8.61(s,1H),7.50–7.44(m,1H),7.42–7.36(m,3H),7.32(dd,J=10.5,1.0Hz,1H),7.24–7.17(m,2H),6.89(tt,J=7.3,1.2Hz,1H),6.63(t,J=6.1Hz,1H),4.36(d,J=6.0Hz,2H),1.29(s,12H).
MS(ESI)m/z 371.19(M+H)+.
(4)叔丁基4-(4-(3-氟-4-((3-苯基脲基)甲基)苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐的制备
将4-(4-氯)叔丁基-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(358mg,0.77mmol),1-(2-氟-4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苄基)-3-苯基脲(368mg,1mmol)和碳酸钾(213mg,1.54mmol)加入瓶中,加入4mL二氧六环和2mL水,室温搅拌均匀,加入Pd(dppf)Cl2(56mg,0.077mmol),氩气保护下加热至100℃反应7h。将反应冷却至室温,加水,减压抽滤,收集滤液,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=2:1,得浅黄色固体428mg,收率82.63%,熔点85-86℃。
1H NMR(400MHz,DMSO-d6)δ8.91(s,1H),8.61(s,1H),7.78(s,1H),7.50(d,J=4.2Hz,2H),7.45–7.35(m,3H),7.21(ddd,J=9.8,5.8,2.3Hz,2H),6.95–6.84(m,1H),6.69(t,J=
6.0Hz,1H),5.66(s,2H),5.45–5.18(m,1H),4.43(d,J=5.9Hz,2H),3.74(s,2H),3.57(dd,J=8.5,7.4Hz,2H),3.23(t,J=5.5Hz,2H),1.95(s,2H),1.39(s,9H),0.91–0.78(m,2H),-0.08(s,9H).
MS(ESI)m/z 673.34(M+H)+.
(5)1-(4-(5-(1-(丁-2-炔酰基)-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)-3-苯基脲的制备
将叔丁基4-(4-(3-氟-4-((3-苯基脲基)甲基)苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(204mg,0.303mmol)加入瓶中,加入2.5mL无水乙醇,室温搅拌均匀,滴加浓盐酸(1.2mL,15.15mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥,浓缩得油状物。将油状物溶于3mL二氯甲烷,在冰盐浴的条件下加入DIEA(160μL,0.909mmol)和NaOH(17mg,0.42mmol),滴加2-丁炔酰氯(50μL,0.5454mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得白色固体98mg,收率50.63%,熔点151-152℃。
1H NMR(500MHz,DMSO-d6)δ8.91(s,1H),8.61(s,1H),7.79(d,J=20.3Hz,1H),7.46(d,J=7.1Hz,2H),7.41–7.37(m,2H),7.20(t,J=7.8Hz,2H),6.89(t,J=7.4Hz,1H),6.75–6.59(m,2H),6.18–6.02(m,1H),5.66(s,2H),4.41(d,J=5.8Hz,2H),3.92(s,2H),3.58(t,J=8.1Hz,2H),3.46(d,J=25.4Hz,2H),2.01(d,J=31.9Hz,2H),1.24(s,3H),0.86–0.83(m,2H),-0.08(s,9H).
MS(ESI)m/z 639.34(M+H)+.
(6)标题化合物的制备
将1-(4-(5-(1-(丁-2-炔酰基)-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)-3-苯基脲(64mg,0.1mmol)溶于1.5mL二氯甲烷,在冰浴条件下滴加三氟乙酸(670μL,9mmol),室温搅拌7h。在冰浴条件下加入NaOH水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得白色固体31mg,收率61.02%,熔点156-157℃。
1H NMR(400MHz,DMSO-d6)δ12.38(s,1H),9.00(d,J=9.6Hz,1H),8.83(s,1H),7.60(dd,J=13.9,2.4Hz,1H),7.47(dt,J=14.7,8.0Hz,2H),7.40(d,J=7.6Hz,3H),7.20(t,J=7.9Hz,2H),7.00–6.93(m,1H),6.88(t,J=7.3Hz,1H),5.30(d,J=28.5Hz,1H),4.42(d,J=5.5Hz,2H),4.03(dd,J=14.2,7.1Hz,1H),3.85(s,1H),3.60–3.54(m,1H),3.46–3.38(m,1H),1.98(d,J=7.2Hz,5H).
HRMS calcd.For C29H26O2N6F(M+H)+509.2096,found 509.2087.
实施例18
1-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-7H-吡咯并[2,3-d]嘧啶-4-基)-2-氟苄基)-3-苯基脲
(1)1-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-)d]嘧啶-4-基)-2-氟苄基)-3-苯基脲的制备
将叔丁基4-(4-(3-氟-4-((3-苯基脲基)甲基)苯基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-d]嘧啶-5-基)-3,6-二氢吡啶-1(2H)-羧酸盐(204mg,0.303mmol)加入瓶中,加入2.5mL无水乙醇,室温搅拌均匀,滴加浓盐酸(1.2mL,15.15mmol),室温搅拌10h。冰浴条件下加入饱和碳酸氢钠溶液调pH至7~8,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥,浓缩得油状物。将油状物溶于3mL二氯甲烷,在冰盐浴的条件下加入DIEA(160μL,0.909mmol)和NaOH(17mg,0.42mmol),滴加丙烯酰氯(55μL,0.682mmol),室温搅拌3h。加水,二氯甲烷萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,柱层析分离,洗脱剂为石油醚:乙酸乙酯=1:1,得白色固体93mg,收率48.97%,熔点67-68℃。
1H NMR(500MHz,DMSO-d6)δ8.91(s,1H),8.61(s,1H),7.79(d,J=20.3Hz,1H),7.42(dd,J=39.5,7.4Hz,5H),7.20(t,J=7.7Hz,2H),6.89(t,J=7.4Hz,1H),6.69(dt,J=18.5,7.9Hz,2H),6.12(td,J=10.9,9.8,6.0Hz,1H),5.65(d,J=10.6Hz,3H),5.32(d,J=100.4Hz,1H),
4.41(d,J=5.8Hz,2H),3.92(s,2H),3.58(t,J=8.2Hz,2H),3.46(d,J=25.4Hz,2H),2.01(d,J=31.9Hz,2H),0.85(t,J=7.7Hz,2H),-0.08(s,9H).
MS(ESI)m/z 627.35(M+H)+.
(2)标题化合物的制备
将1-(4-(5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-7-((2-(三甲基甲硅烷基)乙氧基)甲基)-7H-吡咯并[2,3-)d]嘧啶-4-基)-2-氟苄基)-3-苯基脲(63mg,0.1mmol)溶于1.5mL二氯甲烷,在冰浴条件下滴加三氟乙酸(670μL,9mmol),室温搅拌7h。在冰浴条件下加入NaOH水溶液调pH至7~8,室温搅拌1.5h。加水,乙酸乙酯萃取三次,饱和氯化钠溶液洗1次,无水硫酸钠干燥。浓缩,得白色固体25mg,收率50.40%,熔点187-188℃。
1H NMR(400MHz,DMSO-d6)δ12.30(d,J=10.0Hz,1H),8.78(s,1H),8.63(s,1H),7.61–7.51(m,1H),7.37(dd,J=27.4,7.0Hz,5H),7.15(t,J=7.8Hz,2H),6.84(t,J=7.3Hz,1H),6.64(dd,J=17.0,5.6Hz,2H),6.06(dd,J=17.7,6.0Hz,1H),5.60(dd,J=23.2,11.4Hz,1H),5.21(d,J=92.2Hz,1H),4.36(d,J=5.7Hz,2H),3.86(s,2H),3.47–3.33(m,2H),2.01(s,1H),1.92(s,1H).
HRMS calcd.For C28H26O2N6F(M+H)+497.2096,found 497.2111.
药理实验
实验例1、对BTK的抑制活性
实验目的:对本发明化合物进行体外BTK的抑制活性评价。
实验方法:实验使用来自Promega Corporation的ADP-GloTM检测试剂盒。共设置了11个浓度(10μM至1nM)。将50μL化合物添加到384孔稀释板中,并使用Echo将每行0.05μL稀释的化合物溶液转移到384测定板中,每列包含2个重复。将2.5μL酶工作液加入384孔检测板中,与化合物在25℃孵育15分钟。加入2.5μL底物工作液引发反应,60min后加入4μL ADP Glo试剂。60min后,加入8μL激酶检测试剂,25℃孵育60min。用envision Perkin Elmer读板器(Envision,PE,USA)读取发光信号。
实验结果:如表1-1所示,本发明化合物具有较高的BTK抑制活性,绝大多数半数抑制浓度IC50小于10nM。如表1-2所示,多个化合物的活性与阳性对照依鲁替尼相当。
表1-1本发明化合物对BTK蛋白的抑制活性范围
注:抑制活性分级,“A”表示IC50值小于10nM,“B”表示IC50值在10nM与100nM之间,“C”表示IC50值在100nM与1000nM之间,“D”表示IC50值大于1000nM。
表1-2本发明化合物对BTK蛋白的抑制活性数值
实验例2、对TMD-8细胞的增殖抑制活性
实验目的:本实验通过检测化合物在TMD8细胞系中对体外细胞活性的影响而研究化合物抑制细胞增殖的作用。Ibrutinib为内控化合物。
实验方法:实验采用了96孔板的体外筛选体系,在每孔中加入95μL细胞悬液,在
Min对照孔中加入不含细胞(含0.1%DMSO)的培养液。取5μL的20×化合物工作液加入到细胞培养板中。在Max对照中加入5μL DMSO细胞培养液混合液。DMSO终浓度为0.1%。将培养板在37℃,5%CO2培养箱中培养72小时。
用CellTiter-Glo发光法进行细胞活性检测。SpectraMax Paradigm读数得出对应的每孔荧光值RLU。细胞增殖抑制率(Inhibition Rate)数据采用下列公式来处理:
Inhibition Rate(Inh%)=100-(RLUDrug-RLUMin)/(RLUMax-RLUMin)*100%。在EXCEL中计算不同浓度化合物对应的抑制率,然后用GraphPad Prism软件作抑制率曲线图并计算相关参数,参数包括细胞最大和最小抑制率,IC50值。
实验结果:如表2-1所示,本发明化合物具有较高的TMD-8增殖抑制活性,绝大多数半数抑制浓度IC50小于10nM。如表2-2所示,多个化合物的活性优于阳性对照依鲁替尼。
表2-1本发明化合物对TMD-8增殖抑制活性范围
注:抑制活性分级,“A”表示IC50值小于10nM,“B”表示IC50值在10nM与100nM之间,“C”表示IC50值在100nM与1000nM之间,“D”表示IC50值大于1000nM。
表2-2本发明化合物对TMD-8增殖抑制活性数值
实验例3、体内药代动力学研究
实验目的:测试实施例化合物的体内药代动力学参数
实验方法:选用雄性BALB/c小鼠,分别为口服给药组和静脉注射组。对于口服给药组,10mg/kg剂量口服给药,分别于5min,10min,15min,30min,1h,2h,4h,6h,8h,12h于眼眶静脉丛交叉取血。对于静脉注射组,2mg/kg剂量静脉注射给药,分别于2min,5min,10min,15min,30min,1h,2h,4h,6h,8h,12h于眼眶静脉丛交叉取血。用离心法制备血浆,建立标准曲线,加入乙腈沉淀血浆蛋白后,用液相色谱-质谱联用(LC-MS/MS)分析上清液。绘制药时曲线,用WinNonLin软件分析数据,经非房室模型拟合,得到血浆药代动力学参数。
实验结果:如表3所示,口服剂量为10mg/kg时,实施例8化合物的口服生物利用度为40.98%,口服剂量为25mg/kg时,实施例8的口服生物利用度达到96.56%,而阳性药依鲁替尼的口服生物利用度只有4%。与阳性药相比,实施例8改善了BTK不可逆抑制剂生物利用度较低的问题。
表3口服给药和静脉注射给药实施例8后小鼠的药代动力学参数a
a药代动力学参数为3次实验测定结果的平均值。
实验例4、体内药效学研究
实验目的:测试实施例化合物8的体内抗肿瘤活性
实验方法:选用雌性CB17SCID小鼠,皮下接种TMD8细胞,在肿瘤平均体积达到约150-200mm3时开始分组给药。以依鲁替尼为阳性对照药,按照25mg/kg的剂量口服给药;对于本发明的化合物,分别按照12.5mg/kg、25mg/kg和50mg/kg的剂量口服给药。连续给药21天,每天两次。
实验结果:如图1所示,实施例化合物8低中高三个剂量组对肿瘤均有抑制作用,且高剂量组对肿瘤的抑制作用和阳性药依鲁替尼相当。本发明中的化合物8展现了较强的体内抗肿瘤活性,为弥漫大B淋巴瘤等的治疗提供了新的选择。
Claims (10)
- 如通式(I)所示的化合物或其药学上可接受的盐:
其中,R选自且R3选自丙烯酰基,2-丁炔酰基;R1,R2取代基为一个或多个,选自H,C1-8直链或支链烷基,C3-8环烷基,C1-8烷氧基,C1-8烷基氨基,卤素,羟基,氨基,氰基,且所述的C1-8直链或支链烷基进一步被一个或多个卤素,羟基,氨基或氰基取代。 - 根据权利要求1所述的化合物或其药学上可接受的盐,其特征在于,R1,R2选自H,甲基,乙基,正丙基,异丙基,正丁基,异丁基,叔丁基,正戊基,异戊基,环丙基,环丁基,环戊基,甲氧基,乙氧基,丙氧基,甲基氨基,乙基氨基,F,Cl,Br,I,羟基,氨基,氰基,或者选自被一个或多个卤素取代的甲基,乙基,正丙基,异丙基,正丁基,异丁基,叔丁基,正戊基,异戊基。
- 根据权利要求1所述的化合物或其药学上可接受的盐,其特征在于,R1选自H,甲基,乙基,三氟甲基,F,Cl,Br,或I;R2选自H,异丙基,异丁基,叔丁基,异戊基,环丙基,环丁基,环戊基。
- 根据权利要求1所述的化合物或其药学上可接受的盐,其特征在于,所述的化合物结构为:
- 权利要求1-4任一项的化合物或其药学上可接受的盐的制备方法,其特征在于,步骤如下:路线(1):
试剂与条件:(a)(2-(氯甲氧基)乙基)三甲基硅烷,碳酸钾,N,N-二甲基甲酰胺,室温;(b)N-Boc-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯,1,1'-二(二苯膦基)二茂铁二氯化钯,碳酸钾,1,4-二氧六环,100℃;(c)R1,R2取代苯基硼酸频哪醇酯,1,1'-二(二苯膦基)二茂铁二氯化钯,碳酸钾,1,4-二氧六环,100℃;(d)盐酸的乙醇溶液,室温;丙烯酰氯,N,N-二异丙基乙胺,二氯甲烷,室温;(e)三氟乙酸,二氯甲烷,室温;四氢呋喃溶液,氢氧化钠溶液,室温;路线(2):
试剂与条件:(a)(2-(氯甲氧基)乙基)三甲基硅烷,碳酸钾,N,N-二甲基甲酰胺,室温;(b)N-Boc-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯,1,1'-二(二苯膦基)二茂铁二氯化钯,碳酸钾,1,4-二氧六环,100℃;(c)R1,R2取代苯基硼酸频哪醇酯,1,1'-二(二苯膦基)二茂铁二氯化钯,碳酸钾,1,4-二氧六环,100℃;(d)氢气,钯碳,乙酸乙酯溶液,甲醇溶液,室温(e)盐酸的乙醇溶液,室温;丙烯酰氯,N,N-二异丙基乙胺,二氯甲烷,室温;(f)三氟乙酸,二氯甲烷,室温;四氢呋喃溶液,氢氧化钠溶液,室温;其中R1、R2的定义同权利要求1-4任一项所述。 - 一种药物组合物,其特征在于,所述药物组合物中包含权利要求1-4中任一项所述的化 合物或其药学上可接受的盐以及药学上可接受的载体。
- 权利要求1-4中任一项所述的化合物或其药学上可接受的盐在制备治疗与BTK功能相关的疾病的药物中的应用。
- 权利要求1-4任一项所述的化合物或其药学上可接受的盐在制备治疗类风湿性关节炎、系统性红斑狼疮的药物中的应用。
- 权利要求1-4任一项所述的化合物或其药学上可接受的盐在制备治疗非霍奇金性淋巴瘤药物中的应用。
- 权利要求1-4任一项所述的化合物或其药学上可接受的盐在制备治疗华式巨球蛋白血症、慢性淋巴细胞白血病或原发性中枢神经系统淋巴瘤药物中的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210581611.4 | 2022-05-26 | ||
CN202210581611.4A CN117164591A (zh) | 2022-05-26 | 2022-05-26 | 吡咯并嘧啶类化合物,其制备方法及制药用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023226580A1 true WO2023226580A1 (zh) | 2023-11-30 |
Family
ID=88918392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/084066 WO2023226580A1 (zh) | 2022-05-26 | 2023-03-27 | 吡咯并嘧啶类化合物,其制备方法及制药用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117164591A (zh) |
WO (1) | WO2023226580A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103917545A (zh) * | 2011-07-19 | 2014-07-09 | 默沙东公司 | Btk抑制剂 |
CN105153154A (zh) * | 2014-09-26 | 2015-12-16 | 广东东阳光药业有限公司 | Btk抑制剂及其用途 |
CN113583007A (zh) * | 2021-08-31 | 2021-11-02 | 山东大学 | 一种吡咯并嘧啶类btk抑制剂及其制备方法与应用 |
-
2022
- 2022-05-26 CN CN202210581611.4A patent/CN117164591A/zh active Pending
-
2023
- 2023-03-27 WO PCT/CN2023/084066 patent/WO2023226580A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103917545A (zh) * | 2011-07-19 | 2014-07-09 | 默沙东公司 | Btk抑制剂 |
CN105153154A (zh) * | 2014-09-26 | 2015-12-16 | 广东东阳光药业有限公司 | Btk抑制剂及其用途 |
CN113583007A (zh) * | 2021-08-31 | 2021-11-02 | 山东大学 | 一种吡咯并嘧啶类btk抑制剂及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN117164591A (zh) | 2023-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI398252B (zh) | 吡咯并嘧啶化合物及其用途 | |
CN102203063B (zh) | 咔唑化合物及其治疗用途 | |
EP3398950B1 (en) | Novel kinase inhibitor against wild-type egfr and mutated egfr | |
US10829491B2 (en) | Pyrimido[5,4-B]indolizine or pyrimido[5,4-B]pyrrolizine compound, preparation method and use thereof | |
CN108602805A (zh) | Mnk1和mnk2的异吲哚啉、氮杂异吲哚啉、二氢茚酮和二氢氮杂茚酮抑制剂 | |
AU2018208231B2 (en) | Imidazopyrazine compound, preparation method therefor and use thereof | |
CN110662536B (zh) | 激酶网络抑制剂及其用途 | |
TW201040162A (en) | Inhibitors of JAK | |
CN102250065B (zh) | 取代的三嗪苯脲衍生物及其用途 | |
CN105452235A (zh) | 取代的喹唑啉-4-酮衍生物 | |
IL175572A (en) | Condensed heterocycles, jak selective kinase inhibitors and pharmaceutical compositions comprising them | |
CN114650990B (zh) | 抑制tyk2活性的杂环类化合物 | |
CN102227422A (zh) | 杂环jak激酶抑制剂 | |
TWI523856B (zh) | BCR-ABL kinase inhibitor and its application | |
CN105968115B (zh) | 喹啉类化合物、其制备方法、中间体、药物组合物和应用 | |
WO2014079232A1 (zh) | 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用 | |
WO2020135507A1 (zh) | 一种多取代苯氨基嘧啶衍生物及其制备方法和用途 | |
KR20170018084A (ko) | Ral gtpases를 타겟으로 하는 항암용 화합물 및 이의 사용방법 | |
CN116669738A (zh) | 一种作为sos1抑制剂的嘧啶并吡啶酮类衍生物、其制备方法及用途 | |
CN108473487B (zh) | 一种蛋白激酶抑制剂 | |
WO2023226580A1 (zh) | 吡咯并嘧啶类化合物,其制备方法及制药用途 | |
WO2023024545A1 (zh) | Fgfr4抑制剂、组合物及其在药物制备中的用途 | |
TWI546304B (zh) | Protein tyrosine kinase inhibitors and their use | |
JP2022511477A (ja) | Ire1小分子阻害物質 | |
WO2017088289A1 (zh) | 用作jak激酶抑制剂的4,7-二氨基-吡咯并[2,3-d]嘧啶衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23810655 Country of ref document: EP Kind code of ref document: A1 |